<!DOCTYPE html><html lang="zh-CN"><head><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta charset="utf-8"><meta property="qc:admins" content="10210420621156375"><meta name="renderer" content="webkit"><title>zangyn - 雪球</title><script>var _write = document.write;
var write = function (str) {
  SNB = window.SNB || {};
  if (_write.apply) {
    SNB.docWrite = function (str) {
      _write.apply(document, arguments);
    }
  } else {
    SNB.docWrite = _write;
  }
};

document.write = write;
</script><meta name="keywords" content="zangyn - 雪球"><meta name="description" content="zangyn - 雪球"><!--<link rel="shortcut icon" href="http://xueqiu.com/favicon.ico">--><link rel="icon" type="image/png" href="http://assets.imedao.com/images/favicon.png"><style>html {display:none}</style><script>if (self == top) {
  document.documentElement.style.display = 'block';
} else if (top.location.host !== 'xueqiu.com') {
  top.location = self.location;
}
var WATCH = {};
WATCH.appStart = 1427781338842
WATCH.pageStart = (new Date()).getTime()</script><link rel="stylesheet" href="http://assets.imedao.com/style/bootstrap-84b5ee.css"><style>body{
  padding-top:40px;
}
/* TODO */
.search .dropdown-menu strong{
  height:12px;
  line-height:12px;
}</style><link rel="apple-touch-icon-precomposed" href="http://assets.imedao.com/images/icon-144.png"><script src="http://assets.imedao.com/js/xdomain-0.6.15.js"></script><script>xdomain.slaves({
  'https://xueqiu.com': '/proxy2.html',
  'https://im0.xueqiu.com': '/proxy2.html',
  'https://im1.xueqiu.com': '/proxy2.html',
  'https://im2.xueqiu.com': '/proxy2.html',
  'https://im3.xueqiu.com': '/proxy2.html',
  'https://im4.xueqiu.com': '/proxy2.html',
  'https://im5.xueqiu.com': '/proxy2.html',
  'https://im6.xueqiu.com': '/proxy2.html',
  'https://im7.xueqiu.com': '/proxy2.html',
  'https://im8.xueqiu.com': '/proxy2.html',
  'https://im9.xueqiu.com': '/proxy2.html'
});</script><script src="http://assets.imedao.com/js/SNB.lib.bundle-b11b47.js"></script></head><body id="his-profile" class=" isPC isNotMobile isNotPad"><script>SNB = window.SNB || {};
jQuery.extend(SNB, {
  data: {},
  env: "production",
  Views: {},
  Templates: {},
  Models: {},
  Collections: {},
  domain: {"host":"http://xueqiu.com","base":"http://api.xueqiu.com","photo":"http://photo.xueqiu.com","stock":"http://api.xueqiu.com","static":"http://assets.imedao.com","staticHttps":"https://js.xueqiu.com","upyun":"http://xqimg.b0.upaiyun.com","pdf":"http://doc.xueqiu.com","im":"http://api.xueqiu.com","shared":"/data/source/snowball-fe/shared/","file":"http://xqfile.imedao.com/"},
  currentUser: {"isGuest":true,"enableIM":true},
  jsVersion: {"05.jquery.cookie.js":"68e2a4","08.templates.js":"4aa7bf","SNB.TopicList.js":"870445","SNB.UsersList.js":"34f02b","SNB.atDialog.js":"b5dce3","SNB.base.js":"0e6b16","SNB.base_simple.js":"8d5f63","SNB.bind_verify.js":"118df1","SNB.calendar.js":"c65d9a","SNB.calendarDialog.js":"929cb0","SNB.calendarSubscribe.js":"e6012c","SNB.capitalReturnRateChart.js":"bd11c3","SNB.cardDialog.js":"ab3d1d","SNB.commentView.js":"bbb8d8","SNB.commonFriends.js":"230e08","SNB.companyInfo.js":"86e7f2","SNB.dialog.js":"1ba7c4","SNB.dm.js":"4c9d34","SNB.dmDialog.js":"c96117","SNB.downloadDialog.js":"68595d","SNB.editor.emotion.js":"ccd772","SNB.editor.js":"adb8a9","SNB.eventShare.js":"7b230c","SNB.financeTableDataInfo.js":"63138a","SNB.follower.js":"83577e","SNB.friends.js":"d90729","SNB.g.bar.js":"8d17c0","SNB.guest.js":"a94f90","SNB.guide.js":"28902b","SNB.helpers.js":"d5327e","SNB.his_home.js":"468d25","SNB.holdStockChart.js":"7fb688","SNB.home.js":"da999e","SNB.hotStock.js":"320cd1","SNB.im.contacts.js":"3d5779","SNB.im.dialog.js":"ee29f9","SNB.im.emotions.js":"158b2d","SNB.im.group_applys.js":"5c11f0","SNB.im.group_joined.js":"3f1895","SNB.im.js":"43351a","SNB.im.message.js":"1c9f8a","SNB.im.model.js":"a8324f","SNB.im.net.js":"ec4486","SNB.im.peer_chat.js":"cb13f1","SNB.im.session_item.js":"bbffaa","SNB.im.sessions_list.js":"eb2ad1","SNB.im.setting.js":"ac0ed0","SNB.im.stranger.js":"8ea9a5","SNB.im.utils.js":"6a455e","SNB.imeigu_fund_topic.js":"712871","SNB.imeigu_index.js":"d4f2e9","SNB.index.login.js":"bba5e1","SNB.inner_trade.js":"7d8321","SNB.interest.js":"eeb1f8","SNB.interview.js":"fa9ef6","SNB.kline.js":"b097fb","SNB.lib.bundle.js":"b11b47","SNB.lib.mobile.js":"8eda9f","SNB.modify_email.js":"0cb2c6","SNB.newChart.js":"453bf1","SNB.newChart.mobile.js":"089c9a","SNB.newProfile.js":"50704d","SNB.password.js":"8bf5ac","SNB.pdfDialog.js":"edc173","SNB.performance-year.js":"55e5b8","SNB.performance.js":"b83bda","SNB.performanceChart.js":"0cc6bc","SNB.performanceView.js":"fde3d9","SNB.performance_mobile.js":"2890ea","SNB.personality.js":"3a3a3d","SNB.portfolio.js":"b332e5","SNB.portfolioNew.js":"291c15","SNB.portfolioShareDialog.js":"b581bf","SNB.profile_info.js":"621d95","SNB.recommend.js":"0444f1","SNB.renderTableTrHtml.js":"d9ecf0","SNB.renderUserView.js":"0ea1a6","SNB.reportSpam.js":"418c1f","SNB.repostDialog.js":"7df4cb","SNB.sameFriend.js":"b18a13","SNB.search.js":"11b42e","SNB.search_ipad.js":"62a216","SNB.search_stock_ipad.js":"6910d7","SNB.setting_user.js":"5d7e30","SNB.shareDialog.js":"1dee89","SNB.similarUsers.js":"72068a","SNB.singleStock.js":"2f733b","SNB.status-edit.js":"a9ae8a","SNB.status.js":"1172f0","SNB.status_mobile.js":"7e19fa","SNB.stockActiveUser.js":"396eeb","SNB.stockFollowers.js":"e124c9","SNB.stockList.js":"941ade","SNB.stockList_new.js":"e5b606","SNB.stockNews.js":"311d94","SNB.stockRecommend.js":"352bad","SNB.stockScreener.js":"352de4","SNB.stockStatus.js":"7af8bd","SNB.talks.js":"e19cae","SNB.third_oauth.js":"1b9e2a","SNB.tipsTalk.js":"83e04f","SNB.tipsTopic.js":"624f0b","SNB.today.js":"ff42db","SNB.today.lib.js":"19681e","SNB.today_topic.js":"9f7844","SNB.tooltip.js":"b57764","SNB.topInfluence.js":"89f31e","SNB.trans.js":"ae4d82","SNB.tweetDialog.js":"9eb539","SNB.typeahead.js":"6c0b76","SNB.userRecommend.js":"5dcade","SNB.userRemark.js":"001ff1","SNB.validator.js":"32794c","SNB.weiboUser.js":"81e080","TGJSBridge.js":"4aaeff","WdatePicker.js":"eb9586","ajaxfileupload.js":"59627b","backbone.0.9.10.js":"5d519b","backbone.js":"d013f1","bootstrap.js":"6bd6fa","calendar.js":"9795e3","checkLogin.js":"38a9a1","config.js":"799ccf","d3.v2.min.js":"1ef3b6","fittext.js":"45db6e","flexpaper.js":"56a735","flexpaper_handlers.js":"623c12","fullcalendar.js":"26781c","g.bar.js":"32785d","g.line-min.js":"2db247","g.pie.js":"46e2f1","g.raphael.js":"630b74","hammer.js":"ec2456","hc_exporting.js":"bb5d9e","hc_grid.js":"3b9851","highcharts.js":"122285","highlight.js":"21d2c6","iScroll.js":"834870","im2014.js":"0216be","im_group_apply.js":"930e3b","imeigu_portfolioIframe.js":"8e3134","imgPlugin.js":"1cb5de","imgUpload.js":"0986a1","infinity.min.js":"0c5941","jquery.color.js":"875798","jquery.galleriffic.js":"e6186f","jquery.hammer.js":"e02a44","jquery.history.js":"6f8651","jquery.imgareaselect.js":"a9d059","jquery.js":"d80a03","jquery.lazyload.min.js":"fb3951","jquery.mousewheel.js":"41ebd2","jquery.pjax.js":"7ccac8","jquery.plugin.pullToRefresh.js":"35465b","jquery.rotate.1-1.js":"60d180","jquery.simplePagination.js":"420bda","jquery.tagsinput.js":"0dce2d","jquery.ui.js":"9ee05e","jquery.uploadify.js":"aac61a","jquery.validate.js":"555531","jquery.vticker.js":"5104ed","jquery.watermark.js":"0cc691","login.js":"094d42","moment.js":"b01d4e","morris.min.js":"92098e","mustache.js":"fbf1b1","perfect-scrollbar-0.4.8.with-mousewheel.min.js":"1bd536","raphael.js":"ea1c64","responsive_slides.min.js":"ea733a","sea.js":"1264a2","share-to-xueqiu.js":"ae4237","single.js":"36ac66","slides.jquery.js":"cd66ff","step01.js":"ceaeeb","subscribe.js":"7d760a","underscore.js":"51b489","userSearch.js":"54d13d","xdomain-0.6.15.js":"575cd5","xdomain.js":"c4e376","zepto.js":"6cdcc6","My97DatePicker/WdatePicker.js":"eb9586","My97DatePicker/calendar.js":"9795e3","SNB.lib.bundle/00.sea.js":"24e81c","SNB.lib.bundle/01.JSON.js":"b459a8","SNB.lib.bundle/02.modernizr.js":"f634b5","SNB.lib.bundle/03.jquery.js":"53538f","SNB.lib.bundle/04.jquery.ui.js":"96c17c","SNB.lib.bundle/05.jquery.cookie.js":"68e2a4","SNB.lib.bundle/06.underscore.js":"d97ed3","SNB.lib.bundle/07.backbone.js":"8a9a44","SNB.lib.bundle/08.templates.js":"4aa7bf","SNB.lib.bundle/10.jade.runtime.js":"1fc7ae","SNB.lib.mobile/1.zepto.min.js":"acaeac","SNB.lib.mobile/2.underscore.js":"c2da07","SNB.lib.mobile/iscroll.js":"4a55be","bootstrap/bootstrap-alert.js":"a9f081","bootstrap/bootstrap-button.js":"ce03ae","bootstrap/bootstrap-carousel.js":"62b76a","bootstrap/bootstrap-collapse.js":"9be616","bootstrap/bootstrap-dropdown.js":"af96b6","bootstrap/bootstrap-modal.js":"cf302e","bootstrap/bootstrap-popover.js":"a4e6a7","bootstrap/bootstrap-scrollspy.js":"a88d39","bootstrap/bootstrap-tab.js":"8f2b45","bootstrap/bootstrap-tooltip.js":"682437","bootstrap/bootstrap-transition.js":"17fa23","bootstrap/bootstrap-typeahead.js":"97f107","common/SNB.helpers.js":"2bdc5e","common/backbone_1.1.2.js":"8531c9","common/css3-mediaqueries.js":"f83d37","common/fastclick.js":"753522","common/jquery-1.9.1.js":"b8b878","common/json.js":"b459a8","common/lib.js":"de2f7c","common/sea-2.3.0.js":"c823d9","common/sea.js":"24e81c","common/underscore_1.6.0.js":"3ffba8","common/util.js":"183faf","common/zepto-core-fx.1.1.3.js":"27e274","common/zepto-deferred.js":"977158","cube/cube_detail.js":"b26446","cube/cube_detail_m.js":"1ea5eb","cube/cube_discover.js":"b16cdd","cube/cube_discover_m.js":"b9ea8b","cube/cube_edit.js":"d058ee","cube/cube_guide.js":"88a7d5","cube/cube_recommend.js":"eb4aa8","cube/post_grid.js":"730811","cube/profile_cubes.js":"593e28","cube/range_slider.js":"358302","cube/stock_edit_modal.js":"9ad913","highcharts/jquery-1.6.4.min.js":"526f75","im2014/base.adapter.deliver.js":"17ba5b","im2014/base.adapter.js":"e895d8","im2014/base.config.js":"710ff1","im2014/base.js":"58869d","im2014/base.localstorage.js":"57720d","im2014/base.net.js":"540257","im2014/base.utils.js":"8cb3f7","im2014/db.contacts.js":"536985","im2014/db.groups.js":"aebe8f","im2014/db.js":"b1164d","im2014/db.message.helper.js":"0fa7e8","im2014/db.messages.js":"cd2db6","im2014/db.sessions.js":"b428e2","im2014/im.js":"3675e3","im2014/session.dialog.js":"34f336","im2014/session.editor.js":"fc99c9","im2014/session.gmm.js":"44c0a0","im2014/session.item.js":"2f722e","im2014/session.joingroup.js":"34f898","im2014/session.list.js":"35a7ff","im2014/session.message.js":"30b56c","im2014/session.setting.js":"a5fdcb","im2014/widget.emotion.js":"e07cbb","im2014/widget.joingroup.js":"b2ee4c","im2014/widget.requestjoingroup.js":"319aaa","im2014/widget.search.js":"2d2eda","im2014/widget.uploader.js":"e1abec","im2014/widget.viewer.js":"93c152","imeigu/xueqiu_popup.js":"61979d","lang/en.js":"c6550c","lang/zh-cn.js":"a606a6","lang/zh-tw.js":"4e0fdb","lib/autoresize.js":"f853a5","lib/chai.js":"a0130d","lib/jquery.easing.1.3.js":"008f85","lib/jquery.fullPage.js":"f69025","lib/mocha.js":"8799cd","lib/store.js":"9c7667","lib/ueditor.js":"2e0f51","lib/upload.js":"8837c4","pages/home.js":"1112bf","pages/single.js":"0a3e7d","widget/TSNB.addfriend.js":"f04fd7","widget/TSNB.addpdf.js":"d185b8","widget/TSNB.addstock.js":"0c459a","widget/TSNB.at.js":"a5ebeb","widget/TSNB.bindverify.js":"f3ea69","widget/TSNB.home-editor.js":"123ca2","widget/TSNB.newuser-guide.js":"3bc710","widget/TSNB.people-autocomplete.js":"92ed61","widget/TSNB.performance.js":"27b5e6","widget/TSNB.sharestatus.js":"16e249","widget/TSNB.stockalert.js":"1cb0fd","widget/TSNB.stockgroup.js":"7baec6","widget/TSNB.typeahead.js":"6e6634","widget/aside.js":"46008f","widget/backbone1.1.2.js":"181b4a","widget/bootstrap.js":"abac2a","widget/donate.js":"312591","widget/donate_tooltip.js":"435b5f","widget/editor.js":"25fcd3","widget/emotions.js":"623bc3","widget/favorite.js":"e356ee","widget/forward.js":"fb609b","widget/global_pin.js":"4c1878","widget/lodash.underscore.js":"1854ff","widget/profile_pin.js":"fb4311","widget/report_spam.js":"2e5e63","widget/repost_comment.js":"4bb3ae","widget/share.js":"6e71c0","widget/status.js":"d06d1e","widget/underscore1.6.0.js":"4d7fd6","widget/util.js":"c0629c","My97DatePicker/lang/en.js":"c6550c","My97DatePicker/lang/zh-cn.js":"a606a6","My97DatePicker/lang/zh-tw.js":"4e0fdb","bootstrap/tests/phantom.js":"e38dfa","bootstrap/tests/server.js":"21e92a","common/lib/jquery-1.9.1.js":"3dd6ee","common/lib/sea-2.3.0.js":"c823d9","common/lib/underscore_1.6.0.js":"834fa8","common/util/image.js":"73664d","common/util/jade.runtime.js":"aed6b5","common/util/jquery.extend.js":"cb4243","common/util/observer.js":"648151","common/util/password.js":"ef4528","common/util/upload.js":"8f1294","pages/about/app.js":"eecbff","pages/about/app_mobile.js":"7db607","pages/broker/TSNB.bind.js":"e8ed5d","pages/consultant/consultant-market.js":"2bc801","pages/event/TSNB.year-summary-mobile.js":"73f230","pages/event/TSNB.year-summary.js":"daff60","pages/event/cmc.js":"a7c273","pages/home/timeline.js":"1112bf","pages/invest/SNB.chart_base.js":"285f6f","pages/invest/SNB.fund_chart.js":"4a2cb1","pages/invest/SNB.mobile_chart.js":"bc032b","pages/invest/SNB.mobile_stock.js":"d942d7","pages/invest/SNB.profile_broker_rank.js":"85311d","pages/invest/SNB.rank.js":"677dd5","pages/invest/chart.js":"02e6ce","pages/pay/deposit-mobile.js":"799d95","pages/pay/deposit.js":"e37ac4","pages/pay/donate-mobile.js":"153feb","pages/pay/pin.js":"1804ea","pages/pay/subscribe-mobile.js":"c6187b","pages/pay/withdraw.js":"952521","pages/sns/index.js":"a6c885","pages/sns/single.js":"120bdc","pages/today/mobile.index.js":"f72378","pages/user/login.js":"ff5499","widget/aside/TSNB.ad.js":"55466e","widget/aside/TSNB.hot-stocks.js":"44327c","widget/aside/TSNB.interesting-people.js":"b01b82","widget/aside/TSNB.other-services.js":"70e391","widget/aside/TSNB.recommend-people.js":"7ddb30","widget/aside/TSNB.sysnotify.js":"e50d01","widget/aside/TSNB.today-talk.js":"8fa37c","widget/bootstrap/affix.js":"f014e8","widget/bootstrap/alert.js":"915f20","widget/bootstrap/bootstrap-datepicker.js":"daa8d6","widget/bootstrap/button.js":"3a8a2e","widget/bootstrap/carousel.js":"f763e0","widget/bootstrap/collapse.js":"c9ceab","widget/bootstrap/dropdown.js":"164604","widget/bootstrap/modal.js":"d390dd","widget/bootstrap/popover.js":"8c9993","widget/bootstrap/scrollspy.js":"37bd38","widget/bootstrap/tab.js":"5df6c4","widget/bootstrap/tooltip.js":"b973d7","widget/bootstrap/transition.js":"7af948","widget/bootstrap/typeahead.js":"1e1e67","widget/editor/at.js":"41b184","widget/editor/emotion.js":"bd52eb","widget/editor/umeditor.config.js":"ed3336","widget/editor/umeditor.js":"6b7121","widget/editor/zh-cn.js":"16b3e4","widget/flexpaper/flexpaper.js":"56a735","widget/flexpaper/flexpaper_handlers.js":"39b20d","widget/mobile/action.js":"43495d","widget/mobile/form.js":"03c77e","widget/mobile/modal.js":"309f6a","widget/mobile/overlay.js":"44e1eb","widget/status/comment.js":"239e91","widget/status/data.js":"d2678b","widget/status/pdf.js":"0af8cc","widget/status/pin.js":"4dce9c","widget/tmp/SNB.base.js":"73a62a","widget/tmp/json.js":"b459a8","widget/util/TSNB.donate.js":"dabf92","widget/util/areas.js":"4f6252","widget/util/modal.js":"0a947f","widget/util/notice.js":"c2c3a1","widget/util/share.js":"8c017a","widget/util/tooltip.js":"30a8e8","widget/util/typeahead.js":"f70471","widget/util/user.js":"9b9c3a","bootstrap/tests/unit/bootstrap-alert.js":"93d6ac","bootstrap/tests/unit/bootstrap-button.js":"996b53","bootstrap/tests/unit/bootstrap-carousel.js":"54a2cf","bootstrap/tests/unit/bootstrap-collapse.js":"1b1262","bootstrap/tests/unit/bootstrap-dropdown.js":"6a491c","bootstrap/tests/unit/bootstrap-modal.js":"6dd5a0","bootstrap/tests/unit/bootstrap-phantom.js":"940ffb","bootstrap/tests/unit/bootstrap-popover.js":"4f65eb","bootstrap/tests/unit/bootstrap-scrollspy.js":"bd7b2c","bootstrap/tests/unit/bootstrap-tab.js":"63f9fc","bootstrap/tests/unit/bootstrap-tooltip.js":"fc2c1c","bootstrap/tests/unit/bootstrap-transition.js":"a1b2cc","bootstrap/tests/unit/bootstrap-typeahead.js":"2f86e0","bootstrap/tests/vendor/jquery.js":"fcf997","bootstrap/tests/vendor/qunit.js":"a8c0db","pages/invest/chart/TSNB.chart.base.js":"33cd3a","pages/invest/chart/TSNB.chart.compare.js":"6b4c52","pages/invest/chart/TSNB.chart.event.js":"23af89","pages/invest/chart/TSNB.chart.kline.js":"3a1e79","pages/invest/chart/TSNB.chart.status.js":"62d5f1","pages/invest/chart/TSNB.chart.stock.js":"770897","pages/invest/chart/TSNB.chart.thumbnail.js":"52101d","pages/invest/hq/TSNB.compare_ah.js":"8dcaea","pages/invest/portfolio/TSNB.create-portfolio-group.js":"d9e67b","pages/invest/portfolio/TSNB.delete-portfolio-group.js":"af94fb","pages/invest/portfolio/TSNB.delete-portfolio.js":"1a6838","pages/invest/portfolio/TSNB.manage-portfolio-group.js":"1b0504","pages/invest/portfolio/TSNB.portfolio-util.js":"d78b8f","pages/invest/portfolio/TSNB.portfolio.js":"6580b6","pages/invest/portfolio/TSNB.stock-autocomplete.js":"cc5d2e","pages/sns/index/cube.js":"1f5d94","pages/sns/index/login.js":"665dd7","pages/sns/index/markets.js":"b51353","pages/sns/index/promotion.js":"aa01d3","pages/sns/index/stocks.js":"47fe9b"},
  cssVersion: {"about.css":"8a68c7","activate_bar.css":"90db89","bootstrap-lite.css":"09c973","bootstrap.css":"84b5ee","bootstrap_full.css":"66069a","bootstrap_tab_xueqiu.css":"69dee9","bootstrap_tab_xueqiu_white.css":"5492e5","button.css":"23513c","chart.css":"d41d8c","comment.css":"dbfbd5","connect_link.css":"0edf0b","default.css":"165b51","default_mobile.css":"264592","dh.css":"a34780","dialog.css":"828547","editor.css":"57d8ef","editor_inline.css":"7d7563","flexpaper.css":"ecc108","form.css":"c845bd","fullcalendar.css":"b1f726","guide_overlay.css":"9dd1cf","hots-statuses.css":"181d4e","icon.css":"680a07","im.css":"aa2f71","im2014.css":"dbd489","imgroup.css":"5445f8","jinNang.css":"4bd30a","jinnang_1394597838763.css":"4bd30a","jquery.tagsinput.css":"3f47e0","jquery.ui.css":"279647","mentions_block.css":"4b58aa","mocha.css":"a5dea9","mystatus.css":"272433","newChart.css":"5d9be9","pdfviewer.css":"720dd9","performance-year-mobile.css":"a17f1a","performance-year.css":"317994","performanceChart.css":"2589d4","personality-ie8.css":"6a37b0","personality.css":"c723c4","pop_login.css":"8f20df","portfolioIframe.css":"c85adf","portfolioNew.css":"4f2887","profile.css":"0737fc","profile_info.css":"4b5978","profile_operations.css":"a0abbd","profile_status.css":"01d683","pull-to-refresh.css":"3e5b69","searchBar.css":"aeef28","simplePagination.css":"b23401","snowbrick.css":"ccc31a","status_mobile.css":"4c93b3","status_operate_btn.css":"0872af","tab-setting.css":"506d45","today_topic.css":"a8f864","tooltip.css":"820355","uploadify.css":"d5b49f","userRecommend.css":"beabbe","user_list.css":"bb06fd","widget.css":"88e99b","widget_user.css":"d1e0c0","common/base.css":"2262f2","common/grid.css":"ad0354","common/iconfont.css":"5cf08f","common/layout.css":"746a95","common/menu.css":"985468","common/mobile.css":"3362b1","common/mod.css":"e27423","common/modal.css":"f9111d","common/nav-bar.css":"c37184","common/pager.css":"0d5b09","common/reset.css":"e2dffc","common/var.css":"d41d8c","cube/cube_card.css":"ae3e1a","cube/cube_detail.css":"d97083","cube/cube_detail_m.css":"9ac92d","cube/cube_discover.css":"30d439","cube/cube_discover_m.css":"d02a1d","cube/cube_edit.css":"f5208f","lib/jquery.fullPage.css":"3dfa38","pages/TSNB.about.css":"28449a","pages/home.css":"3ef6f1","pages/imeigu.css":"d51b5b","pages/post.css":"16fd7a","pages/profile.css":"093e27","pages/status.css":"cc43c8","pages/tip.css":"9bc5a0","touch/common.css":"1c57df","touch/normal.css":"d536b7","widget/TSNB.comment.css":"705fe6","widget/TSNB.donate.css":"708f8a","widget/TSNB.donate_tooltip.css":"672acf","widget/TSNB.performance.css":"588cce","widget/TSNB.portfolio_dialog.css":"68b2cb","widget/TSNB.portfolio_user_dialog.css":"9ad4f2","widget/TSNB.report_spam.css":"3e795c","widget/TSNB.share.css":"f36d77","widget/TSNB.status.css":"024cfd","widget/TSNB.user_dialog.css":"81075a","widget/btn.css":"9fdda0","widget/datepicker.css":"d683e7","widget/donate.css":"ab255d","widget/donate_tooltip.css":"9e0336","widget/global_pin.css":"92b1cf","widget/modal.css":"5fc4e9","widget/profile_pin.css":"60296d","common/css3/inline-block.css":"bb8c38","pages/about/animation.css":"1e4355","pages/about/app.css":"d919d8","pages/about/app_mobile.css":"5b4c12","pages/about/share.css":"6712c8","pages/consultant/consultant.css":"138686","pages/event/TSNB.year-summary-mobile.css":"864fa2","pages/event/TSNB.year-summary.css":"a868f5","pages/event/cmc-mobile.css":"7fe9f7","pages/event/cmc.css":"8d1acc","pages/home/home-editor.css":"a4a479","pages/home/newuser-guide.css":"23dd61","pages/home/widgets.css":"cfae61","pages/index/cube.css":"cc49b2","pages/index/default.css":"417e7b","pages/invest/dealList.css":"79d551","pages/invest/mobile_chart.css":"31d833","pages/invest/mobile_performance.css":"16e7bb","pages/invest/mobile_stock.css":"4a4c6d","pages/invest/profile_broker_rank.css":"55a18e","pages/invest/rank.css":"4d6196","pages/invest/stock_chart.css":"0eeda7","pages/mobile/common.css":"004801","pages/mobile/vars.css":"d41d8c","pages/pay/subscribe-mobile.css":"128827","pages/pay/wallet-mobile.css":"583bc0","pages/pay/wallet.css":"f7af19","pages/pin/pin-mobile.css":"bf2ba8","pages/sns/TSNB.single.css":"775597","pages/sns/home.css":"8f62db","pages/today/index-mobile.css":"a95cc9","pages/user/login.css":"ba73c8","widget/bootstrap/alerts.css":"2c520b","widget/bootstrap/badges.css":"da050d","widget/bootstrap/bootstrap.css":"971848","widget/bootstrap/breadcrumbs.css":"b9ab35","widget/bootstrap/button-groups.css":"a7c65b","widget/bootstrap/buttons.css":"a73cc0","widget/bootstrap/carousel.css":"93e128","widget/bootstrap/close.css":"30812b","widget/bootstrap/code.css":"fab06a","widget/bootstrap/component-animations.css":"63295e","widget/bootstrap/dropdowns.css":"d91661","widget/bootstrap/forms.css":"1dac09","widget/bootstrap/glyphicons.css":"024db0","widget/bootstrap/grid.css":"7f9bd0","widget/bootstrap/input-groups.css":"fc56c7","widget/bootstrap/jumbotron.css":"cf17ad","widget/bootstrap/labels.css":"3e0971","widget/bootstrap/list-group.css":"ec9751","widget/bootstrap/media.css":"ecbd91","widget/bootstrap/mixins.css":"a0cb66","widget/bootstrap/modals.css":"5b2682","widget/bootstrap/navbar.css":"abacbf","widget/bootstrap/navs.css":"9fbe5c","widget/bootstrap/normalize.css":"ddcb0b","widget/bootstrap/pager.css":"7be0a4","widget/bootstrap/pagination.css":"eaa566","widget/bootstrap/panels.css":"d53a2d","widget/bootstrap/popovers.css":"93bafa","widget/bootstrap/print.css":"b11602","widget/bootstrap/progress-bars.css":"580cf9","widget/bootstrap/responsive-embed.css":"1c5626","widget/bootstrap/responsive-utilities.css":"2db01f","widget/bootstrap/scaffolding.css":"0fc3a2","widget/bootstrap/tables.css":"462165","widget/bootstrap/theme.css":"52929d","widget/bootstrap/thumbnails.css":"b96eb4","widget/bootstrap/tooltip.css":"c060af","widget/bootstrap/type.css":"c8dff8","widget/bootstrap/utilities.css":"d3b1aa","widget/bootstrap/variables.css":"d41d8c","widget/bootstrap/wells.css":"578e1c","widget/mobile/modal.css":"f2f776","widget/mobile/normal.css":"d536b7","widget/mobile/top-bar.css":"f4eb52","widget/umeditor/editor.css":"5f1892","widget/umeditor/umeditor.css":"7eb569","widget/util/page.css":"3ea87c","pages/home/widgets/ad.css":"4f1e5e","pages/home/widgets/hot-stocks.css":"9c722b","pages/home/widgets/interesting-recommend.css":"25f080","pages/home/widgets/my-nav.css":"c4c64e","pages/home/widgets/other-services.css":"d76f0d","pages/home/widgets/sysnotify.css":"116c48","pages/invest/portfolio/group.css":"3e96d2","pages/invest/portfolio/portfolio.css":"f2f39b","widget/bootstrap/mixins/alerts.css":"d41d8c","widget/bootstrap/mixins/background-variant.css":"d41d8c","widget/bootstrap/mixins/border-radius.css":"d41d8c","widget/bootstrap/mixins/buttons.css":"d41d8c","widget/bootstrap/mixins/center-block.css":"d41d8c","widget/bootstrap/mixins/clearfix.css":"d41d8c","widget/bootstrap/mixins/forms.css":"d41d8c","widget/bootstrap/mixins/gradients.css":"d41d8c","widget/bootstrap/mixins/grid-framework.css":"d41d8c","widget/bootstrap/mixins/grid.css":"2f25b9","widget/bootstrap/mixins/hide-text.css":"d41d8c","widget/bootstrap/mixins/image.css":"d41d8c","widget/bootstrap/mixins/labels.css":"d41d8c","widget/bootstrap/mixins/list-group.css":"d41d8c","widget/bootstrap/mixins/nav-divider.css":"d41d8c","widget/bootstrap/mixins/nav-vertical-align.css":"d41d8c","widget/bootstrap/mixins/opacity.css":"d41d8c","widget/bootstrap/mixins/pagination.css":"d41d8c","widget/bootstrap/mixins/panels.css":"d41d8c","widget/bootstrap/mixins/progress-bar.css":"d41d8c","widget/bootstrap/mixins/reset-filter.css":"d41d8c","widget/bootstrap/mixins/resize.css":"d41d8c","widget/bootstrap/mixins/responsive-visibility.css":"d41d8c","widget/bootstrap/mixins/size.css":"d41d8c","widget/bootstrap/mixins/tab-focus.css":"d41d8c","widget/bootstrap/mixins/table-row.css":"d41d8c","widget/bootstrap/mixins/text-emphasis.css":"d41d8c","widget/bootstrap/mixins/text-overflow.css":"d41d8c","widget/bootstrap/mixins/vendor-prefixes.css":"d41d8c"},
  staticDomain: 'http://assets.imedao.com',
  bid : ''
});

SNB.data.access_token =  $.cookie("xq_a_token") || "7fd433866f17942022661a942c06f2b5fe387c88";
</script><!-- 防止局域网缓存用户信息--><script>(function(){
  var search = window.location.search || '';
  if (search.indexOf('_=') === -1 && SNB.bid !== '' && document.cookie && document.cookie.indexOf('bid=' + SNB.bid) === -1) {
    var searchArr = search.split('&');
    searchArr.push('_=' + (+new Date).toString(36));
    window.location.search = search.join('&');
  }
})();
</script><script src="http://assets.imedao.com/js/05.jquery.cookie.js"></script><script>function delCookie(name){//为了删除指定名称的cookie，可以将其过期时间设定为一个过去的时间
  var date = new Date();
  date.setTime(date.getTime() - 10000);
  document.cookie = name + '=a; expires=' + date.toGMTString();
}
/*
if(!$.cookie('xq_refresh') && $.cookie('xq_a_token')){
  $.ajax({
    url: '/user/refreshCookie',
    async: false
  }).done(function(){
    delCookie('xq_a_token');
    delCookie('xq_r_token');
    delCookie('xq_token_expire');
  });
}
*/
jQuery(function($){
  $('.navbar a.exit').on('click', function(){
    try{
      delCookie('xq_a_token');
      delCookie('xq_r_token');
      delCookie('xq_token_expire');
    } catch(e){
      console.log(e);
    }
  });
});</script><script src="http://assets.imedao.com/js/SNB.helpers-d5327e.js"></script><script>SNB.profileUser = {"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200896,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":130,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png!50x50.png","profile_image_url_small":"community/default/avatar.png!30x30.png"}</script><noscript><style>html {
  display: block
}</style><p class="ie6">当前浏览器禁用了JavaScript，导致不能正常使用雪球的功能，请打开JavaScript后再访问本站。</p></noscript><!--[if lt IE 8]><div class="ie6">你正在使用的浏览器版本过低（IE7或IE7以下，包括套用了IE内核的360浏览器、搜狗浏览器等）。<br />如果不能正常浏览本站或某些功能无法使用，请到微软官网下载升级 <a href="http://windows.microsoft.com/zh-CN/internet-explorer/downloads/ie">Internet Explorer</a> 或使用 <a href="http://www.google.com/chrome/">谷歌 Google Chrome</a> 浏览器。</div><![endif]--><div class="temp"></div><div class="navbar navbar-fixed-top"><div class="navbar-inner"><div class="container"><h1 id="logo"><a href="/"><img title="返回我的首页" src="http://assets.imedao.com/images/logo@2x.png" width="54px" height="30px" alt="雪球"></a></h1><div class="search"><form method="get" action="/k"><input id="quick-search" name="q" type="text" autocomplete="off" placeholder="搜索 股票/讨论/用户/群组" class="typeahead"></form><span class="icon"><i></i></span></div><ul class="nav pull-right account notlogined"><li><a href="/account/reg" class="reg">注册</a></li><li><a href="/" class="login">登录</a></li></ul></div></div></div><!--!=css('im.css')--><script>seajs.config({
  timeout: 60000,
  preload: [SNB.jsVersion && _.keys(SNB.jsVersion).length ? 'SNB.base-' + SNB.jsVersion['SNB.base.js'] + '.js' : 'SNB.base.js']
})
</script><script>seajs.use("SNB.guest.js")
</script><script>;(function () {
  var keys = _.keys(SNB.jsVersion)
    , map = [];
    
  if (keys.length) {
    _.each(keys, function(k) {
      var reg = new RegExp('\\/(' + k.replace(/\./g, '\\.') + ')(\\?.*|$)');
      
      map.push([reg, function (all, fileName, param) {
        var result = '/' + fileName.replace(/\.js$/i, '') + '-' + SNB.jsVersion[k] + '.js';
        
        if (param) {
          result += param;
        }
        
        return result;
      }]);
    });
    
    seajs.config({
      map: map
    });
  }
}())
</script><!-- test config--><script src="http://assets.imedao.com/js/bootstrap-6bd6fa.js"></script><div id="center" class="container"><div class="main"><div style="display:none" class="loading"></div><div class="wrapper"><link rel="stylesheet" href="http://assets.imedao.com/style/pages/profile-093e27.css"><div class="profile_box container "><div class="profile_box_behaviour"><div class="profile_box_operations"><div class="profile_operations"><ul class="operations relation"><li class="relationship"><span class="op addFriendBtn"><b>＋</b>加关注</span></li><li><a href="javascript:;" data-toggle="at" data-target="zangyn" class="at">@他</a></li><li><a href="javascript:;" class="block">拉黑</a></li><li><a href="javascript:;" class="reportSpam_user">举报</a></li></ul></div></div><div class="profile_box_users"><div style="display:none" class="usersList similarUser_list head-list"></div><script>seajs.use('SNB.similarUsers.js', function(){
  var collection=new SNB.Collections.similarUsers();
  collection.fetch({
    success:function(){
      var col_length = collection.length;
      if(col_length){
        var views=new SNB.Views.similarUsersList({el:$(".similarUser_list"),collection:collection});
        views.render();
        $(".similarUser_list").prepend("<h3>兴趣相近</h3>").show();
      }
    }
  })
})</script></div></div><div class="profile_box_info"><div class="profile_info"><div class="profile_info_pic"><img src="http://xavatar.imedao.com/community/201210/1352439404964-20121221.png!100x100.png" width="100" height="100"/></div><div class="profile_info_content"><h2><span>zangyn</span><a href="＃" style="display:none" data-user-id='6785033954' data-user-name="zangyn" class="setRemark">(备注)</a></h2><script>seajs.use("SNB.base.js", function(){
  SNB.get("/user/profile/show.json", {uid: SNB.profileUser.id, property: "card_sid,personality"}, function(data) {
    $(".profile_info_content h2").append("<a target='_blank' title='雪球名片' style='margin-left:6px' href='" + SNB.profileUser.profile + "/card'><img title='雪球名片' src='http://assets.imedao.com/images/card/" + (data[0]?'namecard-icon2.png':'namecard-icon2-gray.png') + "'/></a>")
    var p = data[1] && data[1].value != 'false';
    $(".profile_info_content h2").append("<a target='_blank' title='投资者性格" + (p ? '：' + SNB.Util.personalityResult(data[1].value) : '') + "' style='margin-left:6px' href='/event/personality/x/" + (SNB.profileUser.domain || SNB.profileUser.id) + "'><img title='投资者性格" + (p ? '：' + SNB.Util.personalityResult(data[1].value) : '') + "' src='http://assets.imedao.com/images/personality/icon_character" + (p ? '' : '_gray') + ".png'/></a>")
  })
})</script><ul><li class="gender_info"><span class="m head"></span>男&nbsp;&nbsp;&nbsp;海外澳大利亚&nbsp;&nbsp;&nbsp;</li><li>股票130只&nbsp;&nbsp;讨论7506条&nbsp;&nbsp;粉丝200896人</li><li><div class="item_title">能力圈：</div><div class="item_content discuss_stock_list"><span title="科大讯飞" class="discuss_stock">科大讯飞，</span><span title="中国平安" class="discuss_stock">中国平安，</span><span title="中信证券" class="discuss_stock">中信证券</span></div></li><li><div class="item_title">简介：</div><div class="item_content expend_in_oneline"><p class="summary">如果不上雪球，你就输在了投资的起跑线上。</p><p style="display:none" class="detail">如果不上雪球，你就输在了投资的起跑线上。<span class="fold_all">收起<i class="newIcon_expend"></i></span></p></div></li></ul></div></div><script>seajs.use("SNB.base.js", function(){
  SNB.get("/account/oauth/user/show.json",{source:"sina",userid:SNB.profileUser.id},function(ret){
    if(ret && ret.id){
      $(".profile_info").find("ul li").eq(0).append("<a href='http://weibo.com/"+ret.id+"' target='_blank'><span class='newIcon newIcon_weibo'>&nbsp;</span> 微博</a>")
    }
  })
  $(".show_all,.fold_all").on("click",function(e){
    e.preventDefault();
    var that = this;
    $(that).closest(".expend_in_oneline").find("p").toggle();
  })
})</script></div></div><link rel="stylesheet" href="http://assets.imedao.com/style/pages/invest/profile_broker_rank-55a18e.css"><div class="rank-container"><div class="rank-groups newtab"><ul class="nav nav-tabs rank-tabs"></ul><span class="desc">每天的数据将于第二个交易日13:00前更新，由用户及<a href="http://bj.cgws.com/Default.jsp" target="_blank">长城证券</a>授权提供。</span><a href="http://xueqiu.com/3945550771/31966036" class="link">榜单说明</a><a href="http://xueqiu.com/event/rank/gws" class="link">看看其他人</a></div><div class="rank-wrapper"><div class="rank-performance"><div class="performance-title"><span class="title">账户收益</span></div><div class="performance-chart"><div class="performance-info"><div class="performance-income"><div id="pchart"></div><div class="performance-rate"><p class="desc">参赛后的收益率</p><p class="income"> </p><p class="time">参赛时间：-</p><div class="rank-stocks"><p><span class="title">持股前五：</span></p></div></div></div><div class="rank-hold"><div class="rank-day-rate"><p class="data">-</p><p class="desc">日收益</p></div><div class="rank-assets"><p class="data">-</p><p class="desc">净资产</p></div><div class="rank-marketValue"><p class="data">-</p><p class="desc">总市值</p></div><div class="rank-rate"><p class="data">-</p><p class="desc">持仓比例</p></div></div></div></div></div><div class="rank-chart"><div id="capitalReturnRateChartContainer" class="chartContainer"><div class="noData"><span>请您在券商处同步盈亏，或券商暂未支持同步。 </span></div><div class="head"><h3> <a href="/performance">收益率</a></h3><span class="timeInterval"></span><span class="dropdown"><span>业绩对比</span><span class="caret"></span></span></div><div id="ROAStateInfo" class="stateInfo"><span class="stockInfo"><span class="sign"></span><span class="stockName">盈亏 </span><span class="stockUp"></span></span><div class="loadState">数据载入中    </div></div><div id="capitalReturnRateChart"></div><div class="chartInfo"><ul class="selectTime"><li id="1m" class="selected">1月</li><li id="3m">3月</li><li id="6m">6月</li><li id="1y">1年</li><li id="3y">3年</li><li id="5y">5年</li><li id="all">全部</li></ul><span class="info">仅自己可见</span></div><div id="popCompare"><div class="popLeft"><label class="checkbox"> <input type="checkbox" symbol="SH000001"/>上证指数</label><label class="checkbox"> <input type="checkbox" symbol="SZ399001"/>深证指数</label><label class="checkbox"> <input type="checkbox" symbol="HKHSI"/>恒生指数</label><label class="checkbox"> <input type="checkbox" symbol="SP500"/>标准普尔500指数</label><label class="checkbox"> <input type="checkbox" symbol="NASDAQ"/>纳斯达克指数</label><label class="checkbox"> <input type="checkbox" symbol="DJI30"/>道琼斯指数</label><label class="checkbox"> <input type="checkbox" symbol="ICS30"/>i美股中概30指数</label><label class="checkbox"> <input type="checkbox" symbol=""/><input id="searchCompareStock" type="input" placeholder="股票名称/代码"/></label></div><div class="popRight"></div><div class="popClose"><button class="btn">关闭</button></div></div></div><div class="rank-industry"><div class="industry-title">行业分布</div><div class="industry-chart"></div></div></div><div class="rank-tran">   <div class="tran-title"><span class="title">交易历史</span><a href="#" class="show-trans">交易<span class="tran-num"></span>笔，点击查看</a></div><div class="tran-list"></div><div class="hide-tran-list"><a href="#">收起</a></div></div><div class="rank-status"><div class="status-title"><span class="title">关于"百度(BIDU)的讨论"</span><a href="#" class="back-trans">返回交易历史</a></div><div class="tran-status-list"></div></div></div></div><script src="http://assets.imedao.com/js/pages/invest/SNB.profile_broker_rank-85311d.js"></script><style>.cube-follow {
  text-decoration: none;
  cursor: pointer;
}

.cube-follow span {
  display: none;
  width: 20px;
  height: 12px;
  margin:0 3px;
}

.cube-follow-false .add {
  display: inline-block;
  background: url(http://assets.imedao.com/images/profile_cube_image.png) no-repeat -18px -1px;
}

.cube-follow-true .del {
  display: inline-block;
  background: url(http://assets.imedao.com/images/profile_cube_image.png) no-repeat  0px -1px;
}

a.rebalance {

  display: inline-block;
  background: url(http://assets.imedao.com/images/profile_cube_image.png) no-repeat -60px 0px;
  width: 20px;
  height: 12px;
}
a.contact{
  background: url(http://assets.imedao.com/images/profile_cube_image.png) no-repeat -40px 0px;
  display: inline-block;
  width: 20px;
  height: 12px;
}
.limit{
  background: none!important;
  width: auto!important;
  margin: 0!important;
  
}
.moreC{
  background: none;
  border: none;
  color: #0055A2;
  cursor: pointer;
  height: 20px;
  line-height: 20px;
  margin: 0;
  padding: 5px 6px 5px 15px;
  text-align: right;
  border-top: 1px solid #DDD;
}
.none{
  padding: 15px;
  font-size: 14px;
  text-align: center;
  color: #aaa;
}

</style><div class="profile-cube-list portfolioContainer"><div class="cube-title newtab"><ul style="float:left;display:block" class="nav nav-tabs"><li class="active"><a class="nav nav-tabs">他创建的组合(<i class="num">--</i>)</a></li></ul><div class="clear"></div></div><div class="tableContainer"><table><thead><tr><th>组合</th><th>最新净值</th><th>总收益</th><th width="87px">操作</th></tr></thead><tbody><tr><td colspan="4"><div class="loading"></div></td></tr></tbody></table></div></div><script>$.ajax({
  url:"/cubes/count_limit.json",
  data:{
    user_id:SNB.profileUser.id
  },
  type:"get"
}).success(function(data){
  $('.profile-cube-list .cube-title .num').text(data.exists_count);
  $('.profile-cube-list .cube-title .limit').text(data.allow_count);
  
})
seajs.use('cube/profile_cubes.js');
</script><div class="portfolioContainer"><div class="newtab"><ul id="portfolioTab" class="nav nav-tabs"></ul><div class="clear"></div></div><div class="tableContainer"><table class="portfolioNew"><thead><tr><th style="min-width:120px;">股票</th><th style="min-width:40px;">当前价 </th><th style="min-width:80px;">买入目标价</th><th style="min-width:80px;">卖出目标价</th><th>备注</th></tr></thead><tbody><tr><td colspan="7"><div class="loading"></div></td></tr></tbody></table></div></div><script src="http://assets.imedao.com/js/jquery.mousewheel-41ebd2.js"></script><script src="http://assets.imedao.com/js/raphael-ea1c64.js"></script><script>seajs.use('SNB.dialog.js')
seajs.use(['SNB.newChart.js', 'SNB.portfolioNew.js'],function(_c, p){
  var portfolio=new p.Portfolio();
})</script><div class="status_box "><div class="statuses_tab newtab"><ul class="nav nav-tabs"><li id="statusMenu" class="dropdown active status_tab"><a href="#status_content" data-target="#statusMenu" data-type="" data-toggle="dropdown" data-text="主贴(7506)">主贴<b class="caret"></b></a><ul class="dropdown-menu"><li><a href="#status_content" data-toggle="tab" data-type="" data-text="主贴">主贴</a></li><li><a href="#status_content" data-toggle="tab" data-type="0" data-text="原发布">原发布</a></li><li><a href="#status_content" data-toggle="tab" data-type="1" data-text="带标题">带标题</a></li><li><a href="#status_content" data-toggle="tab" data-type="2" data-text="长文章">长文章</a></li><li><a href="#status_content" data-toggle="tab" data-type="3" data-text="交易">交易</a></li></ul></li><li><a href="#favs_content" data-toggle="tab">收藏<small id="favsCount"></small></a></li><li><a href="#friends_content" data-toggle="tab">关注(647)</a></li><li><a href="#followers_content" data-toggle="tab">粉丝(200896)</a></li></ul></div><div class="statuses_container container tab-content"><div id="status_content" class="status_content container active tab-pane"><div class="status_bd"><div id="statusLists" class="allStatuses no-head"></div></div><div class="status_widget"><div class="seachbar"><input id="searchStatus" type="text" autocomplete="off" placeholder="搜索他的讨论" class="placeholder"/><span class="glass"><i></i></span></div><style>.mentionedStocks{
  margin-top:15px;
  display:none;
}
.stocksList{
  border-top:1px solid #F1F1F1;
  margin-top: 8px;
  padding-top: 10px;
  font-size:12px;
}
.stocksList .stockInfo{
  display:inline-block;
  margin-right:5px;
  margin-bottom:8px;
}
.stocksList .stockInfo span{
  color:#888;
  cursor:pointer;
}
</style><div class="mentionedStocks"><h2 class="widget-title">他经常讨论的股票 </h2><div class="fixit"></div><div class="stocksList"></div><div class="fixit"></div><script>seajs.use("SNB.base.js", function(){
  var uid = 6785033954;
  SNB.get("/user/top_status_count_stock.json", { count: 5, uid: uid }, function(stocks){
    if ( stocks && stocks.length ) {
      var html = "";
      _.each(stocks, function(stock, index){
        if ( stock.status_all_count > 0 ) {
          var count = stock.status_all_count,
            name = stock.stockName,
            symbol = stock.symbol,
            title = name + "(" + symbol + ") 查看" + count + "条讨论";
            
          html += '<span class="stockInfo" title="' + title + '" data-name="' + name + '" data-symbol="' + symbol + '" data-count="' + count + '"><a href="#">' + name + '</a><span>(<span class="status_count">' + count + '</span>条讨论)</span></span>';
        }
      });
      if ( html ) {
        $(".mentionedStocks .stocksList").append(html);
        $(".mentionedStocks").show();
      }
    }
  })
})</script></div></div></div><div id="favs_content" class="fade tab-pane"></div><div id="friends_content" class="fade tab-pane"></div><div id="followers_content" class="fade tab-pane"></div></div><style>.seachbar .glass {
  padding:0;
}
.seachbar .glass i{
  background-position:-172px -1px
}</style><script>(function($){
  SNB.data.req_isBrick = 0;
  SNB.data.statuses = {"total":7504,"maxPage":376,"count":20,"statuses":[{"id":22840321,"user_id":6785033954,"title":"胃癌等纳入大病保障范畴 报销比例不低于90%","created_at":1358342164000,"retweet_count":0,"reply_count":0,"fav_count":0,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"央视网消息(新闻联播)：记者今天从卫生部了解到，2013年，我国农村医疗保障重点将向大病转移。肺癌、胃癌等20种疾病全部纳入大病保障范畴，报销比例不低于90%，新农合人均筹资水平将达到340元左右，新农合资金总额增加到2700亿，一些农村地区的大病患者已经成为受益者。 61岁的河南周口农民马继彪...","type":"3","source_link":null,"edited_at":1358342839000,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200896,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/22840321","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":706,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-01-16 21:16","expend":true,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"央视网消息(新闻联播)：记者今天从卫生部了解到，2013年，我国农村医疗保障重点将向大病转移。肺癌、胃癌等20种疾病全部纳入大病保障范畴，报销比例不低于90%，新农合人均筹资水平将达到340元左右，新农合资金总额增加到2700亿，一些农村地区的大病患者已经成为受益者。<br><br>　　61岁的河南周口农民马继彪得了胰头癌、肺癌等好几种病，刚刚在郑州市人民医院做完手术，一共花了7万多块钱，这笔费用相当于他们一家两年的纯收入。<br><br>　　按照之前的政策，合作医疗8000元以上可以报销65%，而今年开始，报销比例有了很大提升，8000元到5万可以报销65%，5到8万报销80%，到了8万以上可以报销90%。数字上的变化，到了农民手里是实实在在的钱。这一场大病，马继彪的医药费报了5万多元，自己只花了不到两万。<br><br>　　现在农民的收入增加了，得了小病一般不会动摇家庭的根基，但是得了大病就会让大部分的家庭因病致贫、因病返贫。<br><br>　　医改以来，国家在推行新农合的同时，也在逐渐把保障的重点向大病转移，向家庭贫困的农民倾斜。除了提高报销标准，肺癌、胃癌、终末期肾病等20种疾病全部纳入大病保障范畴之内，困难农民还将额外得到15%的民政医疗救助基金，这样加起来报销比例不会低于90%。<br><br>　　新农合基金在给农民报销大病医药费时，对医院的用药、治疗要严格的审核，这样既确保钱用到了刀刃上，也保证了农民的治疗效果。农民自己负担的医药费减少了，医院对病人欠费的担心也少了，就能拿出更多的精力来提高服务水平和技术水平。<br><br>　　新农合实际上就是农民的医疗保险，今年每个农民人均筹资标准达到340元左右，其中280元由各级政府来补助，这就意味着新农合资金的大盘子里今年可以给农民报销的钱有2700多亿元，增加的资金将使实际报销的比例提高5个百分点。<br><br>受益股：迪康药业、丰源药业、江苏吴中、华神集团、海欣股份、兰生股份、海正药业、恒瑞医药、双鹭药业。","source":"雪球"},{"id":22836301,"user_id":6785033954,"title":"","created_at":1358314856000,"retweet_count":1,"reply_count":7,"fav_count":0,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"顶部已经在欢呼中诞生，47亿大单夺路出逃。","type":"0","source_link":null,"edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200896,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/22836301","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":627,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-01-16 13:40","expend":false,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"顶部已经在欢呼中诞生，47亿大单夺路出逃。","source":"雪球"},{"id":22823738,"user_id":6785033954,"title":"你应该明白，顶部已经在欢呼中诞生！( 叶荣添 )","created_at":1358209657000,"retweet_count":0,"reply_count":8,"fav_count":4,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"2013年1月14日，我们必须永远铭记这个在将后会被称为“后天”的日子。因为在这一天，中国股市伴随着再一次疯狂的井喷，不仅结束了为期一个月的行情，更在这样万众欢呼的日子里创造了一个几乎没人知道的中期顶部。到了明年的今天所有人回过头来看现在都会发现自己当时是多么可笑，居然会相信这就是...","type":"3","source_link":null,"edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200896,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/22823738","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":600,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-01-15 08:27","expend":true,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"2013年1月14日，我们必须永远铭记这个在将后会被称为“后天”的日子。因为在这一天，中国股市伴随着再一次疯狂的井喷，不仅结束了为期一个月的行情，更在这样万众欢呼的日子里创造了一个几乎没人知道的中期顶部。到了明年的今天所有人回过头来看现在都会发现自己当时是多么可笑，居然会相信这就是牛市的开始。当多数人几乎在未来2个月面临腰斩的结局时，只有少数人能在隔岸光火中虚伪的表示一声叹息，更多的人会以滚下山的姿态去仰望还在山上的人。而这，就是将后会被载入中国股市重要史册的：雪崩行情！他，已经来了！<br><br> &nbsp;&nbsp;这么多年这么多人骂我我都不在乎，我怎么可能还会因为名声就冒天下之大不韪？所以你们可以排除叶荣添是因为所谓踏空而故意逆势看大盘。上篇文章我说过1月14日就会完成2013年的第一次顶部，没错，今天就是。顶部造就的方法不一定要通过下跌来体现，和任何一次底部的诞生需要连续下跌和暴跌砸出来一样，顶部的诞生一样是在连续的疯狂井喷中诞生，如果说1949的底部无人能预料得到是因为他们太为大意和贪心更低的点位而导致的踏空，那么现在的顶部一样也是因为他们太过于自满和兴奋过头人导致在面临了一次重要的底部错失之后，又迎偷赶上了一个重要的顶部诞生。70点的上涨的确完美，无论从成交量的配合还是银行股的又一次强力拉升，一切似乎都在预示着牛市已经开始，加上证监会主席的表态QFII将扩大十倍之后这种对行情的期待从想象牛市到确定牛市而演变，但是钱呢？这是本质。资本市场的一切故事都必须在业绩得到明确后才会开始叙述完整篇章。郭树清所言的QFII扩大十倍只是他自己的意志，这个意志如果想要得到体现就必须有时间来明确什么时候完成？如果扩大十倍是用10年的时间，那这样假借利好而拉升起来的大盘就会很快打回原形。<br><br> &nbsp;&nbsp;各方资金也当然知道这只是主席个人的意志，也因此自上周五突然下跌40点的的疯狂出货后，再一次利用这样大好的做局时间再次用银行股的拉升来向市场宣示行情没有结束，他们深知现在只有用银行拉升市场才会得以相信，因此再次以民生银行等几个大蓝筹为首的权重股扮演起了千里走单骑的角色，平安银行更是用涨停板来告诉世人让下跌见鬼去吧。但是除此之外，和任何一次大盘要面临决堤前的征兆一样400家上点规模的权重股里面70%的股票依然还在1月4日高点的重压之下无法突破，量能依然处于无法放大状态。世人所眼见的仅仅是指数再次创造新高，又一个整数关口被突破，站稳。他们根本不敢正视为什么茅台，平安，联通，新华保险，金地集团，海通证券，中国建筑等等等等这样的无数权重一直处于放量出货，纵使今日拉升其资金买入的量也无法和涨幅相媲美的程度？难道操盘这些的主力是傻子？我一直有所劝诫各位，当这些股票在大盘屡创新高而自身一直被前期高点所压制无法突破甚至处于放量出逃随时准备抽身的状态时，你就必须注意大盘可能会在万众欢呼中迎来一次真正的见顶。如果前面几次这样的拉升还算是意犹未尽发发红包，那么今天的这样一涨你就必须开始真正警惕起来了的。需要警惕的不是下跌，因为这是注定的。真正需要警惕的是，一个月内大盘上涨400点你们觉得不可思议，雪崩来临后更不可思的是大盘可能用20天就全部跌回去。<br><br> &nbsp;&nbsp;这也是今日本文的真正本意，因为我们所经历过，见证过在行情疯狂中突然熄火时间太多。我绝不希望我的兄弟和姐妹在这样的行情中去深套一次。你可以去踏空，但是绝不能接最后一棒。踏空不丢人，也是常事，股市中资金就是士兵永远不怕没什么机会。但是，一旦接了最后一棒，后果可想而知。我依然在等待最佳时机的来临，等待真正崛起的开始。我永远不会在在意谁伤害过我，但是我一定会记住谁让我笑起来。对于我来说有你们就足够了，一个人一辈子会因为100个理由去憎恨一个人，但只有一个理由去原谅一个人，这就是：在乎。希望我是你们所在乎的那个人。不要牺牲在雪上的顶上对于今天在这的所有人来说，这就是在乎两个字所透露出的分量！希望你们能记住，2013年的第一次大顶已经真正诞生。<br><br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;黑暗骑士 叶荣添","source":"雪球"},{"id":22822787,"user_id":6785033954,"title":"医药巨头的2012","created_at":1358179651000,"retweet_count":3,"reply_count":2,"fav_count":6,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"辉瑞 前三季度辉瑞共收入439亿美元,同比下降11%;净利润82.6亿,同比下降4%。立普妥销量继续下滑,Q3全球销量跌幅达71%,前三季度销售额共33.6亿美元。第二畅销药Lyrica 30亿美元的销售额和12%的增长率回天乏力。 今年辉瑞在美国和欧盟、英国共有9个新药获批,包括孤儿药Elelyso、新分子实体药物Inlyta...","type":"3","source_link":null,"edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200896,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/22822787","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":760,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-01-15 00:07","expend":true,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"辉瑞<br><br>前三季度辉瑞共收入439亿美元,同比下降11%;净利润82.6亿,同比下降4%。立普妥销量继续下滑,Q3全球销量跌幅达71%,前三季度销售额共33.6亿美元。第二畅销药Lyrica 30亿美元的销售额和12%的增长率回天乏力。<br><br>今年辉瑞在美国和欧盟、英国共有9个新药获批,包括孤儿药Elelyso、新分子实体药物Inlyta和Bosulif。另外,疫苗沛儿获得了WHO的PQ认证,用于50岁以上人群。<br><br>辉瑞在今年继续实行瘦身计划,以118.5亿美元现金将营养品业务出售给雀巢,接着将动物药业务整体分割出去。辉瑞也斥资6.8亿美元收购了NextWave,一家制造ADHD液体药物的公司。<br><br>中国市场上,辉瑞与浙江海正药业成立的合资公司海正辉瑞开始运营,掘金中国仿制药市场。<br><br>诺华<br><br>前三季度诺华净收入418亿美元,同比下降4%;净利润75亿美元,同比下降2%。2007年后上市的几个药物,前九个月销售额共119亿美元,同比增长24%,其中Gilenya销售额达8.5亿美元,同比增加199%。<br><br>今年分别在美国和欧盟获批的依维莫司,销售已经达到5.2亿,同比增长75%。<br><br>另外,还有COPD药物Seebri Breezhaler 、骨髓纤维化药物Jakavi、库欣病药物Signifor在欧盟获批。<br><br>值得注意的是,诺华今年有两个药物登陆我国,包括重磅药物雷珠单抗,以及昂润比斯海乐。<br><br>默沙东<br><br>前三季度默沙东销售收入355亿美元,同比降低1%;净利润53.5亿美元,同比增加10%。其重磅哮喘药物Singulair由于仿制药获批上市而受到挤压,销售收入33.7亿美元,同比下降16%;糖尿病药物Januvia销售收入29.5亿美元,同比增加25%;宫颈癌疫苗Gardasil销售收入11.9亿美元,同比增加27%。<br><br>新药方面,糖尿病药物JANUMET XR(西他列汀/二甲双胍复方制剂)缓释片和ZIOPTAN(他氟前列腺素)获批。<br><br>其今年默沙东在中国动作频频,与智飞生物签订疫苗开发及销售合同,并与先声药业成立合资公司,瞄准慢性病领域和基层医疗市场。<br><br>赛诺菲<br><br>前三季度赛诺菲净销售额264亿欧元,同比增加6.2%;经营净利润66亿欧元,同比下降1.7%。其中“新健赞”业务板块Q3收入增长率达到22.5%;波立维前三季度销售额15.6亿,同比下降4%;胰岛素Lantus净销售额36亿欧元,同比增长18.1%,其在新兴市场增长率达到31.5%。<br><br>前三季度共有三个新药在美国获批,包括MS药物Aubagio;另外还有第一支语音控制的肾上腺素注射器。<br><br>10月份,赛诺菲宣布正式进军中国医疗器械市场,推出了腹盆腔手术中使用最广泛的防粘连薄膜。同月,宣布收购哥伦比亚制药商Genfar S.A,进驻拉丁美洲新兴市场。<br><br>罗氏<br><br>前三季度罗氏集团销售收入达到337亿瑞士法郎,按恒定汇率计算同比增长4%。不过,瑞士法郎的贬值也有助于罗氏制药营业额上涨。<br><br>重磅药物美罗华、赫赛汀和阿瓦斯汀共贡献了制药部门52%的收入。<br><br>今年获批上市的肿瘤药物Zelboraf, Erivedge 和 Perjeta也为增长做出了贡献。另外, Lucentis和阿瓦斯汀适应征增加,将带来更多增长。<br><br>诊断部门的全球业务也表现出了4%的增长,特别是在新兴市场:其中亚太增长率16%(中国达到了30%),拉丁美洲增长了14%。<br><br>上半年,罗氏提出现金收购对测序平台Illumina,但多次被Illumina董事会驳回,罗氏垄断诊断市场的意图不幸夭折。<br><br>葛兰素史克<br><br>前三季度GSK收入196.3亿英镑,按照恒定汇率计算下降2%;净利润41.4亿英镑。其中仅Seretide/Advair销售额超过10亿,达入37.4亿英镑。疫苗业务部门收入24.6亿英镑。<br><br>欧美及日本市场均出现下滑,仅新兴市场及亚太地区表现出了8%的增长。特别是中国增长了18%。<br><br>9月在欧盟获批的宫颈癌疫苗Cervarix将带来一定增长。<br><br>今年GSK因文迪雅被美国司法部处以了30亿美元的罚单,这是史上最大的医药罚单。<br><br>今年GSK以36亿美元收购了Human Genome Sciences(HGS),以及与盐野义株式会社和ViiV Healthcare达成的共同开发HIV整合酶抑制剂合作协议。<br><br>阿斯利康<br><br>前三季度阿斯利康收入207亿美元,同比下降17%。净利润47.8亿美元,下降21%。重磅药物Crestor销售额46.3亿美元,Nexium收入29亿美元,Symbicort23亿,Seroquel系列 23.3亿。<br><br>美国和西欧地区销售额跌幅达到25%,亚太地区和东欧新兴市场也都出现了下跌,仅中国区表现出19%的增长。<br><br>新药Caprelsa以及ZINFORO在欧盟获批,流感疫苗FluMist? Quadrivalent在美国获批。<br><br>6月,阿斯利康以12.7亿美元的价格收购了专注于小分子治疗方案的美国制药商Ardea;8月,向百时美施贵宝支付37亿美元共同收购Amylin之后,阿斯利康获取了BYETTA? 注射剂和BYDUREON长效注射剂,以及SYMLIN?注射剂和metreleptin。<br><br>强生<br><br>前三季度强生快消领域实现销售收入108亿美元,同比下降3.7%;制药部门收入188.3亿美元,同比增长3%;医疗器械部分实现收入200亿,同比增长3.9%。其重磅药物Remicade实现收入46.6亿;Risperdal Constashouru 10.7亿,Prezista收入10.6亿。<br><br>强生今年有6个新药或者新适应症在欧盟和美国获批,包括拜瑞妥XARELTO成人患者肺动脉栓塞(PE)的治疗及复发性深层静脉(DVT)和PE的预防。不过,与辉瑞联合开发的阿尔茨海默病药物bapineuzumab临床失败。这些药物之前曾被寄予年销售额数十亿美元的希望。<br><br>另外,强生也收到了22亿美元的罚单。<br><br>强生旗下杨森在6月份完成了对德国制药商Corimmun的收购,获得了化合物 COR-1,其在临床前试验中显示出了良好的提升心脏功能的效果。<br><br>雅培<br><br>前三季度雅培销售收入共290.4亿美元,同比增长2%,其中营养品业务销售收入47.6亿美元。<br><br>修美乐成为全球第一畅销药,前三季度销售收入同比上升14.4%,达到了65.9亿美元,超过雅培专利药业务总销售额的50%。修美乐的适应症还在不断拓宽:溃疡性结肠炎在美国和欧盟获批,克罗恩病、以及放射学阴性中轴脊柱关节炎也在欧盟获批。另外,Omnilink Elite血管气球扩张支架系统获FDA批准。<br><br>中国市场上,人附睾蛋白4(HE4)检测方法、维生素D检测方法获得SFDA批准。<br><br>雅培今年以13.5亿美元的价格比利时Galapagos公司在研的类风湿关节炎药物。<br><br>礼来<br><br>前三季度礼来全球销售收入166.5亿美元,同比下降9%;净利润32.6亿美元。畅销药Cymbalta销售收入35.7亿美元,同比增长20%。<br><br>新药方面,Erbitux在美国获批、Jentadueto Cialis在欧盟获批、Tradjenta的新适应症获FDA批准、阿尔茨海默病诊断药物Amyvid先后在美国和欧盟获批、Zyprexa和Cymbalta的新适应症日本获批。<br><br>不过,礼来也遭受了沉重的打击:其已经投入了10亿美元开发的阿尔茨海默病药物Solanezumab仅能轻微减缓轻度阿尔茨海默病患者的认知能力。<br><br>礼来成立中国研发中心,及投资1.4亿美元扩建美国境内胰岛素工厂,显示出其对糖尿病市场的信心,以及增资联亚两千万美元用于生产仿制药,也体现着礼来对中国市场精准的定位。","source":"雪球"},{"id":22822780,"user_id":6785033954,"title":"2012全球医药股：5大赢家 5大输家","created_at":1358179566000,"retweet_count":5,"reply_count":0,"fav_count":6,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"2012年，尽管专利到期的噩耗不断地传来，制药行业整体上的表现仍是喜忧参半，有些公司股票表现强于主要股指，当然也有许多公司表现惨淡。 获利的公司是由于其顶尖药物的强劲利润以及其先进的药物生产流水线，削减成本、裁员和提高工作效率也有助于其利润的积累。亏损的公司主要原因是专利悬崖，其...","type":"3","source_link":null,"edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200896,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/22822780","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":715,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-01-15 00:06","expend":true,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"2012年，尽管专利到期的噩耗不断地传来，制药行业整体上的表现仍是喜忧参半，有些公司股票表现强于主要股指，当然也有许多公司表现惨淡。<br><br>获利的公司是由于其顶尖药物的强劲利润以及其先进的药物生产流水线，削减成本、裁员和提高工作效率也有助于其利润的积累。亏损的公司主要原因是专利悬崖，其他原因还包括研发失败、制造业的混乱以及管理层的崩溃等。<br><br>FiercePharma针对前二十位的大型制药公司，根据2012年第一个交易日和11月23日的收盘价格对比，盘点了2012年股票百分比涨幅最大的前五名公司以及损失率最大的五名公司。详细如下：<br><br>赢家一：吉利德科学公司<br><br>股票代码：$GILD<br><br>初始价格：$41.86<br><br>期末价格：$76.12<br><br>涨幅：81.84%<br><br>吉利德针对特定慢性丙肝患者开发出的口服干扰素结合制剂的流水线处于前列，而且在III期临床试验中针对2型和3型患者临床治愈率为75%，在II期使用药物sofosbuvir的临床试验中，病人治愈率达到了100%。另有一些公司，比如雅培和百时美施贵宝的干扰素疗法药物也表现出较好的前景。<br><br>赢家二：诺和诺德公司<br><br>股票代码：$NVO<br><br>初始价格：669挪威币<br><br>期末价格：921挪威币<br><br>涨幅：37.67%<br><br>由于全球性糖尿病药物的开发，使得诺和诺德的股价表现出增长的趋势，近日，其CEO &nbsp;&nbsp;&nbsp;Lars &nbsp;&nbsp;&nbsp;Sorensen表示，开发出真正的好药，比如Victoza，其将会在9个月里让其股价增长62%，可以帮助丹麦的制药商增加40%的利润。但是目前公司仍会依靠药物Tresiba来提高股价。<br><br>赢家三：安进公司<br><br>股票代码：Amgen<br><br>初始价格：$64.11<br><br>期末价格：$87.6<br><br>涨幅：36.64%<br><br>安进公司有一个10亿的股票回购计划，试图从其关键的贫血药物获利来面对其收入下滑的局面，目前公司发布了一些好消息，即一种可以降低有害胆固醇LDL达到63%的新药，其可以作为立普妥的一个有力竞争者给公司带来利润。<br><br>赢家四：百特<br><br>股票代码：$BAX<br><br>初始价格：$50.54<br><br>期末价格：$68.81<br><br>涨幅：36.15%<br><br>公司一直致力于输入泵相关药物，但是支出占据了其收入的一半，而且在9月份的时候其有30亿元出现了现金负债，近日又有传言说百特公司将收购Gambro公司，如果确实如此，这将使得百特利润增加。<br><br>赢家五：拜耳<br><br>股票代码：BAY<br><br>初始价格：51.05 &nbsp;&nbsp;&nbsp;($66.10)<br><br>期末价格：68.5 &nbsp;&nbsp;&nbsp;($88.69)<br><br>涨幅：34.18%<br><br>相比其它公司的专利悬崖来说，拜耳在很多领域给投资者留下了深刻印象，其抗凝药物-Xarelto具有绝对的竞争力。拜耳CEO表示，他认为华法林替代药物可以每年增加25亿的销售额。实际上总裁表示，如果包括最新的药物Alpharadin和riociguat，最高将可以达到70亿的销售额。<br><br>输家一：第一三共<br><br>股票代码：$JP:4568<br><br>初始价格：1524 &nbsp;&nbsp;&nbsp;yen<br><br>期末价格：1254 &nbsp;&nbsp;&nbsp;yen<br><br>损失：17.72%<br><br>进入2012年以来，Daiichi &nbsp;&nbsp;&nbsp;Sankyo派出了一部分人去印度监督兰伯西的情况，随后公司宣布了FDA关于兰伯西的相关同意情况，这其中花费5亿美元。同时公司最有效的药物稀释剂输给了竞争者Plavix，而且肺癌药物研发也止于最新的一次试验中。<br><br>输家二：葛兰素史克<br><br>股票代码：$GSK<br><br>初始价格：1484.50 &nbsp;&nbsp;&nbsp;pence<br><br>期末价格：1347 &nbsp;&nbsp;&nbsp;pence<br><br>损失：9.26%<br><br>在2月初的时候，公司CEO就表示，2012年对于GSK来说是增长销售额的大好一年，但是事与愿违，由于欧洲药物的大幅降价以及美国非专利药物的降价使其销售额减少量从二分之一到了四分之三。公司也做出过努力，通过解决旧问题并且抓住新的机遇，但是在8月份时，公司在伦敦的交易份额持续下滑。<br><br>输家三：梯瓦<br><br>股票代码：$TEVA<br><br>初始价格：$43.10<br><br>期末价格：$39.71<br><br>损失：7.87%<br><br>公司一直是最大的非专利药物厂商，去年公司抢购了Cephalon公司，将药物Provigil和Nuvigil的生产接手过来，同时其也接受了BMS的交易人Jeremy &nbsp;&nbsp;&nbsp;Levin来作为其总裁。投资者并不确定Levin是否会带领梯瓦进入一个新的过程，而且投资者并不确定梯瓦是否会让其满意，尽管游戏投资者对于前总裁有些不满，因为其在5月份的退休引发了利润的下滑，但是抗多发性硬化药Copaxone也获得了专利的胜利，同时为公司带来了利润。<br><br>输家四：百时美施贵宝<br><br>股票代码：$BMS<br><br>初始价格：$35.01<br><br>期末价格：$32.62<br><br>损失：6.83%<br><br>2012年最戏剧性的莫过于BMS，在8月2日，当其丙肝药物II期临床试验被终止时，其股价下跌，在1月份花25亿购买了药物开发者Inhibitex后，BMS就开始进行试验，结果最后被迫中止。在11月份时，它同辉瑞一同获批进行血液稀释剂Eliquis的开发，而且同阿斯利康也展开合作共用开发糖尿病药物，如果BMS可以说服FDA继续进行这些药物的开发，那么时任总裁Andreotti就会带领公司再次走向光明。<br><br>输家五：阿斯利康<br><br>股票代码：$AZN &nbsp;&nbsp;&nbsp;(London)<br><br>初始价格：3050 &nbsp;&nbsp;&nbsp;pence<br><br>期末价格：2890.50 &nbsp;&nbsp;&nbsp;pence<br><br>损失：5.23%<br><br>阿斯利康失去了其药物抗精神病药-Seroquel的专利保护，而且裁员7300.早在6月份其已经逆转了利润下滑的困境，从6月份的股价2591 &nbsp;&nbsp;&nbsp;pence已经浮动到了如今的2900pence，但是目前其最大的问题是当总裁Soriot实行其新计划的时候，投资者会做出怎样的反应。","source":"雪球"},{"id":22822766,"user_id":6785033954,"title":"2012年生物医药领域25大兼并收购","created_at":1358179493000,"retweet_count":2,"reply_count":0,"fav_count":1,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"当你听到&#34;兼并&#34;这个词时有何感想？一些人可能会想到收购方的竞争力会得到显著提升，而另一些人则会担忧在收购兼并的过程中导致的失业问题。但无论人们对这个问题的评价如何，我们都有极大的必要了解在2012年生物领域发生了哪些大型兼并收购案。 以下是2012年在生物技术、生物医药、分子诊...","type":"3","source_link":null,"edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200896,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/22822766","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":734,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-01-15 00:04","expend":true,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"当你听到&#34;兼并&#34;这个词时有何感想？一些人可能会想到收购方的竞争力会得到显著提升，而另一些人则会担忧在收购兼并的过程中导致的失业问题。但无论人们对这个问题的评价如何，我们都有极大的必要了解在2012年生物领域发生了哪些大型兼并收购案。<br><br>以下是2012年在生物技术、生物医药、分子诊断等领域宣布进行或者已经完成的最大的25起收购案。<br><br>#25. YM Biosciences收购案<br><br>收购方: Gilead Sciences<br><br>收购案金额:五亿一千万美元<br><br>交易宣布日期: 2012年12月12日<br><br>受此消息影响股价变化: 81%<br><br>#24. Proximagen Group收购案<br><br>收购方: Upsher-Smith Laboratories<br><br>收购案金额:五亿七千三百八十万美元<br><br>交易完成日期: 2012年8月14日<br><br>受此消息影响股价变化: 16%<br><br>#23. Amdipharm收购案<br><br>收购方: Mercury Pharma<br><br>收购案金额:五亿九千一百万美元<br><br>交易宣布日期: 2012年10月15日<br><br>受此消息影响股价变化: N/A<br><br>#22. Taro Pharmaceuticals收购案<br><br>收购方: Sun Pharmaceuticals<br><br>收购案金额:6亿美元<br><br>交易宣布日期: 2012年8月13日<br><br>受此消息影响股价变化: -3.6%<br><br>#21. Mustafa Nevzat Pharma收购案<br><br>收购方: Amgen<br><br>收购案金额:7亿美元<br><br>交易完成日期: 2012年6月12日<br><br>受此消息影响股价变化: N/A<br><br>#20. EUSA Pharma收购案<br><br>收购方: Jazz Pharmaceuticals<br><br>收购案金额:七亿一千万美元<br><br>交易完成日期: 2012年6月12日<br><br>受此消息影响股价变化: N/A<br><br>#19. Mercury Pharma收购案<br><br>收购方: Cinven<br><br>收购案金额:七亿四千八百七十万美元<br><br>交易完成日期: 2012年9月3日<br><br>受此消息影响股价变化: N/A<br><br>#18. Healthpoint Biotherapeutics收购案<br><br>收购方: Smith &amp; Nephew<br><br>收购案金额:7亿8千2百万美元<br><br>交易完成日期: 2012年12月24日<br><br>受此消息影响股价变化: N/A<br><br>#17. URL Pharma收购案<br><br>收购方: Takeda Pharmaceutical<br><br>收购案金额: 8亿美元<br><br>交易完成日期: 2012年6月4日<br><br>受此消息影响股价变化: N/A<br><br>#16. Pronova BioPharma收购案<br><br>收购方: BASF<br><br>收购案金额: 8亿6千8百万美元<br><br>交易宣布日期: 2012年11月21日<br><br>受此消息影响股价变化: 24%<br><br>#15. One Lambda收购案<br><br>收购方: Thermo Fisher Scientific<br><br>收购案金额: 9亿2千5百万美元<br><br>交易完成日期: 2012年9月13日<br><br>受此消息影响股价变化: N/A<br><br>#14. Avila Therapeutics收购案<br><br>收购方: Celgene<br><br>收购案金额: 9亿2千5百万美元<br><br>交易完成日期: 2012年3月8日<br><br>受此消息影响股价变化: N/A<br><br>#13. Micromet收购案<br><br>收购方: Amgen<br><br>收购案金额: 11亿6千万元<br><br>交易完成日期: 2012年3月7日<br><br>受此消息影响股价变化: 33%<br><br>#12. Ardea收购案<br><br>收购方: AstraZeneca<br><br>收购案金额:11亿2千6百万美元<br><br>交易完成日期: 2012年6月19日<br><br>受此消息影响股价变化: 54%<br><br>#11. Fougera收购案<br><br>收购方: Novartis<br><br>收购案金额: 15亿2千5百万美元<br><br>交易完成日期: 2012年7月23日<br><br>受此消息影响股价变化: N/A<br><br>#10. Par Pharmaceuticals收购案<br><br>收购方: TPG Capital<br><br>收购案金额:19亿美元<br><br>交易完成日期: 2012年9月28日<br><br>受此消息影响股价变化: 37%<br><br>#9. Dako收购案<br><br>收购方: Agilent Technologies<br><br>收购案金额: 22亿美元<br><br>交易完成日期: 2012年6月21日<br><br>受此消息影响股价变化: N/A<br><br>#8. Inhibitex收购案<br><br>收购方: Bristol-Myers Squibb<br><br>收购案金额: 25亿美元<br><br>交易完成日期: 2012年2月13日<br><br>受此消息影响股价变化: 163%<br><br>#7. Medicis收购案<br><br>收购方: Valeant Pharmaceuticals<br><br>收购案金额:26亿美元<br><br>交易完成日期: 2012年12月11日<br><br>受此消息影响股价变化: 39%<br><br>#6. Boston Biomedical收购案<br><br>收购方: Dainippon Sumitomo Pharma<br><br>收购案金额:26亿3千万美元<br><br>交易完成日期: 2012年4月24日<br><br>受此消息影响股价变化: N/A<br><br>#5. Human Genome Sciences收购案<br><br>收购方: GlaxoSmithKline<br><br>收购案金额: 30亿美元<br><br>交易完成日期: 2012年8月3日<br><br>受此消息影响股价变化: 99%<br><br>#4. Gen-Probe收购案<br><br>收购方: Hologic<br><br>收购案金额: 38亿美元<br><br>交易完成日期: 2012年8月1日<br><br>受此消息影响股价变化: 20%<br><br>#3. Amylin Pharmaceuticals收购案<br><br>收购方: Bristol-Myers Squibb<br><br>收购案金额:53亿美元<br><br>交易完成日期: 2012年8月8日<br><br>受此消息影响股价变化: 101%<br><br>#2. Actavis Group收购案<br><br>收购方: Watson Pharmaceuticals11<br><br>收购案金额:55亿4千7百万美元<br><br>交易完成日期: 2012年10月31日<br><br>受此消息影响股价变化: N/A<br><br>#1. Pharmasset收购案<br><br>收购方: Gilead Sciences<br><br>收购案金额: 112亿美元<br><br>交易完成日期: 2012年1月17日<br><br>受此消息影响股价变化: 90%","source":"雪球"},{"id":22822754,"user_id":6785033954,"title":"20130107-0113 本周医药行业动态","created_at":1358179402000,"retweet_count":0,"reply_count":0,"fav_count":0,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"本周第31届JP摩根健康大会于1.7-10在美国旧金山举行，300家制药、生物技术和医疗健康领域公司的CEO就其公司发展现状和发展目标发表了演讲。JP摩根健康大会是美国及全球医药医疗健康领域聚焦投资，融资和研发合作最重要的会议之一，通过大会日程之内和之外业界同行演讲、讨论和交流，定下了新一年行...","type":"3","source_link":null,"edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200896,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/22822754","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":764,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-01-15 00:03","expend":true,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"本周第31届JP摩根健康大会于1.7-10在美国旧金山举行，300家制药、生物技术和医疗健康领域公司的CEO就其公司发展现状和发展目标发表了演讲。JP摩根健康大会是美国及全球医药医疗健康领域聚焦投资，融资和研发合作最重要的会议之一，通过大会日程之内和之外业界同行演讲、讨论和交流，定下了新一年行业的走向基调。<br><br>----------------------<br><br>1 法国施维雅创始人被控过失杀人罪<br><br>2013-01-10 中国日报<br><br>现年90岁的路易斯·施维雅是施维雅公司的创始人，日前他因涉嫌过失杀人而接受正式调查。<br><br>2011年初，法国制药巨头施维雅公司生产的减肥药“美蒂拓”(Mediator)涉嫌致死数百人，公司被指刻意隐瞒药品副作用、欺骗消费者，如今两年过去了，这桩丑闻仍未平息,日前，施维雅公司的创始人路易斯·施维雅因过失杀人罪接受正式调查。<br><br>----------------------<br><br>2 华海药业打入美国市场<br><br>2013-01-12 浙江日报<br><br>浙江华海药业股份有限公司成功把抗高血压产品氯沙坦钾制剂打入美国连锁店Walgreen。<br><br>华海药业曾经是国内第一家制剂获得美国FDA认证的制药企业，近日成功将成品药卖到美国市场，再次领先国内制药企业。<br><br>----------------------<br><br>3 拜耳完成梯瓦制药兽药部门收购<br><br>2013-01-10 医药经济报<br><br>1月3日，拜耳对外宣称，美国联邦贸易委员会（FTC）已经批准其对梯瓦（Teva）的美国兽药部门的收购。早在去年9月，拜耳就已宣布将斥资1.45亿美元收购该部门。<br><br>兽药被认为是制药企业利润丰厚的领域，随着此次收购，拜耳扩大了其美国兽药业务，希望藉此使得兽药业务获得增长。拜耳和辉瑞、默沙东、赛诺菲以及礼来同属大型兽药供应商。<br><br>----------------------<br><br>4 世界首创人工眼角膜 或诞生千亿规模产业<br><br>2013-01-13 齐鲁网<br><br>11日，世界首创的人工眼角膜，在青岛再次进行猕猴的临床前试验。<br><br>人工眼角膜将在今年连续进行三次猕猴实验后转入临床试验阶段，在进入临床后，一到两年的时间，进入批量生产，批量生产3到5年，达到年产枚左右的产量，达到40亿的产值。<br><br>----------------------<br><br>5 美国最高法院支持政府资助人体胚胎干细胞研究<br><br>2013-01-11 中国科学报<br><br>1月7日，美国联邦最高法院驳回了要求美国政府停止资助人类胚胎干细胞研究的诉讼。<br><br>“谢利诉西贝利厄斯”诉讼案已经走过了3个年头，此前曾有报道称，该斗争已经使得人类胚胎干细胞研究蒙上了一层阴影。日前，部分胚胎干细胞研究支持者们已经开始大肆庆祝法院的决议。他们表示胚胎干细胞研究将带来帕金森氏症、糖尿病和其他疾病的新疗法。<br><br>----------------------<br><br>6 四川禁云南白药胶囊入基药市场<br><br>2013-01-12 网易<br><br>近日，云南白药胶囊被取消四川省基药中标资格及集中上网采购资格，并且企业本身被列入“黑名单”。<br><br>近年来频频登上多地药监局“黑榜”的云南白药，日前受到来自监管层面的处罚。继去年12月19日云南白药胶囊被四川省食品药品监督管理局曝出水分不合格后，近日，四川省药械集中采购工作联席会议办公室发文称，已取消云南白药胶囊的基本药物中标资格及集中上网采购资格，并将企业列入“黑名单”。<br><br>----------------------<br><br>7 化学药降价落地 中成药“避风港”或步后尘<br><br>2013-01-14 慧聪制药工业网<br><br>化学药调价“靴子”刚落地，业内一度风传的中成药调价终于进入轨道。<br><br>1月8日，国家发改委价格司医药价格处处长宋大才指出，“根据本轮药价调整计划，在化学药调价完成之后，我们将在2013年开始调整中成药价格，目前调价的原则和方法还没出来”。<br><br>----------------------<br><br>8 北京将建全国最大养老机构<br><br>2013-01-08 京华时报<br><br>北京市社会福利事务管理中心近日发布消息称，本市将斥资30亿元，打造拥有万张床位，集养老、医疗、娱乐等功能于一体的老年社区，预计“十二五”期间建成。<br><br>目前包括北京在内的多个大城市的老龄化程度日趋增高，中国已经成为“未富先老”国家之一，预计到2050年，北京市60岁以上老年人将达到650万。<br><br>----------------------<br><br>9 1.2亿投资肿瘤诊疗中心 独一味首涉医疗服务业<br><br>2013-01-11 上海证券报<br><br>独一味1月11日公告，公司拟以1.2亿元自有资金收购四川省红十字肿瘤医院肿瘤诊疗中心15年的85%收益权。<br><br>独一味此次受让肿瘤诊疗中心85%的收益权，主要基于公司发展战略的要求。公司此前的产品主要为中药、化学药和生物制药。在明确了医疗服务业将成为公司的第四大产业领域后，本次合作将实现独一味发展医疗服务业的目标，将为公司下一步涉足其他医院产业投资积累经验。<br><br>----------------------<br><br>10 富士胶片Cellvizio共聚焦微探头影像仪通过SFDA审批<br><br>2013-01-11 慧聪制药工业网<br><br>近日，富士胶片（中国）投资有限公司宣布，公司已通过中国国家食品药品监督管理局审批，成功将战略伙伴MaunaKea &nbsp;Technologies公司的“Cellvizio共聚焦微探头影像仪”引入中国，与富士胶片自有品牌内窥镜配合使用，以实现对人体内部组织表层和黏膜细胞结构的同步成像检查。<br><br>“Cellvizio共聚焦微探头影像仪”是一套在内窥镜诊断和治疗过程中，通过内窥镜进入到人体腔道，对体内组织的细胞结构进行可视化检查，为内科医生和研究人员提供显微级、高分辨率实时影像的光学成像系统。","source":"雪球"},{"id":22821538,"user_id":6785033954,"title":"基金增持51只年度业绩暴增股","created_at":1358170839000,"retweet_count":8,"reply_count":2,"fav_count":15,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"上市公司年报披露工作即将拉开帷幕，年报行情逐渐升温，业绩大幅增长公司备受基金青睐。据《证券时报》络数据部统计，51家年度业绩预计增幅在50以上的公司获得基金增持。今年首家摘帽公司领先科技，预计2012年净利润2.703—2.796亿元，同比增幅高达26522.96%。三季度末基金增持14.34%。欧菲光(0024...","type":"3","source_link":null,"edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200896,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/22821538","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":808,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-01-14 21:40","expend":true,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"上市公司年报披露工作即将拉开帷幕，年报行情逐渐升温，业绩大幅增长公司备受基金青睐。据《证券时报》络数据部统计，51家年度业绩预计增幅在50以上的公司获得基金增持。今年首家摘帽公司领先科技，预计2012年净利润2.703—2.796亿元，同比增幅高达26522.96%。三季度末基金增持14.34%。欧菲光(002456,股吧)、普洛股份(000739,股吧)预计净利润增幅超过1000%，基金增持幅度分别为34.83%、353.16%。此外，16家全年业绩增幅超100%的公司也获得不同幅度的基金增持。（何佳）<br><br>　　<br><br>代码简称业绩预告基金持股行业<br>类型摘要测算同比(%)持股数（万股）占已流通A股(%)较上期增减(%)<br>000669领先科技预盈净利润2.703—2.796亿元26522.961844.7624.3114.34电力、煤气及水的生产和供应业<br>002456欧 菲 光预增净利润增长:1518%-1566%1541.832832.4234.2534.83电子<br>000739普洛股份预增净利润增长1355%-1597%1475.871219.664.75353.16医药、生物制品<br>000413宝 石 A预增净利润增长912.63-1081.4%997.011500.005.303.45电子<br>002052同洲电子预盈净利润盈利1.9至2亿元969.251813.986.977.29信息技术业<br>600850华东电脑预增净利润1.7至2亿856.701603.339.3724.40信息技术业<br>000895双汇发展预增净利润增118.83%-127.28%414.262644.904.370.44食品、饮料<br>600312平高电气预增净利润增长400%以上400.002478.073.0321.60机械、设备、仪表<br>600292九龙电力预增净利润上升285%左右285.00973.314.1937.68电力、煤气及水的生产和供应业<br>000531穗恒运A预增净利润增长约250%-300%274.71854.672.53179.52电力、煤气及水的生产和供应业<br>000993闽东电力预增净利润增长200%～250%224.99566.091.527.77电力、煤气及水的生产和供应业<br>002450康 得 新预增净利润增长180%至210%195.007148.9420.799.65石油、化学、塑胶、塑料<br>000697炼石有色预盈净利润约4,200万元188.47416.823.14104.49采掘业<br>002509天广消防预增净利润增长132%至162%147.341319.1217.46210.08机械、设备、仪表<br>002381双箭股份预增净利润增长120%至150%135.0024.090.572.45石油、化学、塑胶、塑料<br>002218拓日新能预盈净利润盈利500-1000万元105.37180.940.3843.36电子<br>600886国投电力预增净利润同比增长将超过100%100.0026344.2712.500.59电力、煤气及水的生产和供应业<br>300132青松股份预增净利润增长100%以上100.00807.4521.4721.54石油、化学、塑胶、塑料<br>600858银座股份预增净利润增长在100%以上100.006148.7112.9731.01批发和零售贸易<br>000979中弘股份预增净利润增加约88%87.725349.8718.076.56房地产业<br>300072三聚环保预增净利润增长84.09%—89.35%86.725878.5428.8621.03石油、化学、塑胶、塑料<br>000982中银绒业预增净利润上升79.54-91.5%85.523102.634.32130.86纺织、服装、皮毛<br>002271东方雨虹预增净利润增长70%至100%85.002335.5311.6538.25金属、非金属<br>002521齐峰股份预增净利润增长60至100%80.00997.458.09135.17造纸、印刷<br>002236大华股份预增净利润增长60至100%80.005285.1217.4519.61电子<br>000671阳 光 城预增净利润增长70%～90%79.304990.519.3717.14房地产业<br>002531天顺风能预增净利润增长60%至90%75.00140.432.2799.07机械、设备、仪表<br>002511中顺洁柔预增净利润变动幅度60%至90%75.00893.699.45539.12造纸、印刷<br>300332天壕节能预增净利润增长64.88%-84.28%74.581202.7615.0315.65社会服务业<br>002635安洁科技预增净利润增长55.18%至85.17%70.17878.6529.2954.96信息技术业<br>300228富瑞特装预增净利润增长约55%-85%70.00816.1811.7961.36机械、设备、仪表<br>300070碧 水 源预增净利润同期增长55%-80%67.504813.9719.135.32社会服务业<br>000887中鼎股份预增净利润增长50-80%65.577328.9812.310.91石油、化学、塑胶、塑料<br>002244滨江集团预增净利润上涨50-80%65.005823.945.1337.47房地产业<br>002421达实智能预增净利润增长50-80%65.001299.3421.45204.99信息技术业<br>002325洪涛股份预增净利润变动幅度45%至85%65.006832.4441.6616.68建筑业<br>002309中利科技预增净利润增长50-80%65.003220.9815.9321.07机械、设备、仪表<br>000705浙江震元预增净利润增长50%-70%60.00467.424.7155.13批发和零售贸易<br>000903云内动力预增净利润增长55-65%60.00307.140.72120.32机械、设备、仪表<br>002138顺络电子预增净利润增长50-65%57.49356.891.274.33电子<br>000858五 粮 液预增净利润增长54.28%-59.16%56.7214020.903.6913.91食品、饮料<br>002364中恒电气预增净利润增长30%至50%56.71569.8215.0170.68机械、设备、仪表<br>002226江南化工预增净利润增长40-70%55.002708.6322.191.85石油、化学、塑胶、塑料<br>002503搜 于 特预增净利润增长40%至70%55.002216.0130.787.81批发和零售贸易<br>000568泸州老窖预增净利润增长50%-60%55.0010709.897.6715.63食品、饮料<br>600521华海药业预增净利润增加50%到60%55.007553.2113.9222.60医药、生物制品<br>002144宏达高科预增净利润增长40%至70%55.00304.053.308.59纺织、服装、皮毛<br>300146汤臣倍健预增净利润增长40%-60%50.001450.3622.2977.32食品、饮料<br>300044赛为智能预增净利润增长40%-60%50.00723.8615.873.40信息技术业<br>002507涪陵榨菜预增净利润增长40%至60%50.00879.7817.6457.76食品、饮料<br>600552方兴科技预增净利润大幅增长-695.355.945.70<br><br>证券时报网","source":"雪球"},{"id":22821141,"user_id":6785033954,"title":"你猜叶荣添最后如何收场？","created_at":1358167398000,"retweet_count":0,"reply_count":7,"fav_count":0,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"2013年的第一次调整：五马分尸！(2013-01-11 00:35:46) 我不愿意装大师，也不想冲圣人。如果一次西藏之行就能改变一个人的全部那我就是在骗你们。在我脱离不了人的范畴之内，我就必须做人做不了的事，所以我不会改变我的看法和观点。更不会去借着一次西藏就当做解脱的借口去看涨来当达到你们想象中...","type":"3","source_link":null,"edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200896,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/22821141","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":763,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-01-14 20:43","expend":true,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"2013年的第一次调整：五马分尸！(2013-01-11 00:35:46)<br><br> &nbsp;我不愿意装大师，也不想冲圣人。如果一次西藏之行就能改变一个人的全部那我就是在骗你们。在我脱离不了人的范畴之内，我就必须做人做不了的事，所以我不会改变我的看法和观点。更不会去借着一次西藏就当做解脱的借口去看涨来当达到你们想象中所谓翻身的目的，如果去西藏能轻易的改变一个人的全部缺点，那西藏现在全部是人了。你们不要把那个地方想的有多么神秘大下之大都是中国的国土，想去的就放心的玩没什么害怕的。对于我这个人来说缺点是太优秀，优点是太自信，你要我改哪里我都不情愿。所以指望着我因为大盘上涨就改变看法随乌合之众一起同流的人们你要失望了，因为从下周开始你们会第一次看到什么叫做被五马分尸！我知道市场不会以我的意志为转移，但是会因为所有人的意外而转移。<br><br> &nbsp;&nbsp;这次上涨的根本是改革，对于改革的预期和信心是支持市场上涨的信心所在。随着时间的深入改革会遇到阻力和派别的斗争。当前大盘无法突破2300点的根本就是在改革这个问题上现在出现了严重的分歧，也有关对于金融市场的改革观点出现的向左的意见。之前一致的改革目标出现了两种需求，这是市场无法继续上涨的根本理由。如果在近期之内高层无法继续给出新的目标和实际的改革走向，对于信心大于实际的股市来说负面信息就会不断传来，从而将之前不容易建立的信心迅速击垮，和之前破罐破摔不同的是由于上涨的太过迅速人们已经习惯相信这个牛市的开始，1949是第四次历史地点并按照这样的思路去布局资金入市。但是在前面三次的历史大底中毫无例外的都是基于实际措施出台后建立的底部，而这一次是建立在信心并无实质的基础上，仅仅是一个40万亿的城镇划对于股市来说机构不会接受这样的利好，这也是为什么从2000点到2300点量能始终无法冲破1000亿的原因，正是谁都见不到实际的资金投入从而不敢贸然入市导致。在这种预期下，银行股有多么的低估值其短期内的价值已经被透支完毕，其他版块如果能抗早就扛了也不会等到现在。也因此，大盘的调整这一次必然会是建立在以改革无法顺利实施为根本，银行涨幅过高为借口，大盘上涨太快为打手的三合一模式下进行。调整从崩盘的演变一开始都不会太快，总让人以为是对于涨幅的正常修复。但往往人们总是抱着这样的侥幸从盈利变成深套最后到无法自拔。在我看来，这一次的调整如果能跌到2200点那么也就意味着将再探1900，你们必须警惕。正常的调整范围会在2220之上进行，跌破了这个点位就直接说明了改革的负面信息将会越来越多，分歧已经到了严重的底部，信心被摧毁只是时间问题。<br><br> &nbsp;&nbsp;&nbsp;自从中国平安在1月4日创出49元的绝世长阴线的时候，中国股市未来2-3个月的顶部其实和他一起就被创造了出来，只是多数人不愿意承认。跟随中国平安一样在1月4日创造出来这根绝世阴线一样的还有无数地产股，券商股，银行股，钢铁股这些大佬。更为关键的是市场偏偏在1月4日新年开盘的第一天造出了利用开门红的心理造出了一个未来短中期内的顶部，意思很明显就是利用场内的暗号在提示各路诸侯一些不能明言的东西，这个东西就是：改革问题！要明确大盘没有到顶其实也是这个指标，什么时候中国平安突破了1月4日开门红的这个阴线，大盘就会真正的突破2300冲击2500，如果这根阴线不被突破大盘也就不要指望了，重压之下的一切指数都是虚假的。无论大盘再怎么折腾，平安的这根阴线代表的始终是场内最大资金在最特殊时刻的坚决撤走，能再次突破就预示着他们回来了，否则就是依然在场外观望。中国股市没有几个人比我更了解中国平安的性格和走势，以我对她的感觉来说我知道大盘从下周一开始就会正式结束自12月4日以来的反弹。12月4日开始的反弹在1月14日结束，40天的时间完成了接近400点的涨幅，无论对于之前套牢的人来说还是踏空的人来说，这都是一个极限，剩下的事情就交给股指期货了。B股最近的猛烈上涨就是场内最近为了避险而对于资本的提前迁移。<br><br> &nbsp;&nbsp;真正的决战似乎已经开始，如果叶荣添是个无赖我会借口我去了一趟西藏得到灵魂的重组而改变看法，但是我没有。我依然坚持我之前的观点，是因为我从来不愿意抛弃信仰，也能深深的感觉到变盘时刻的来临。我知道这样的调整从一开始人们只会认为是对于涨幅的修复，但是随着时间的深入会演变成深套，重套不仅将你们之前大盘反弹而得来的盈利而亏光，更会因为再次重套而无法自拔。我必须再次重申：1949绝不是底部！中国股市，将从下周开始上演车裂大戏，迎来2013年的第一次调整。如果将后人们称作这次调整是五马分尸的话，那么这五匹撕碎中国股市的马将是：中国平安，贵州茅台，民生银行，工商银行，中国人寿！<br><br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;你的兄弟，黑暗骑士！","source":"雪球"},{"id":22815913,"user_id":6785033954,"title":"","created_at":1358130946000,"retweet_count":1,"reply_count":3,"fav_count":0,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"<a href=\"http://xueqiu.com/S/SH600535\"   target=\"_blank\">$天士力(SH600535)$</a> 恭喜天士力再创新高，国家战略奠定天士力两千亿市值基石，两市最佳中线投资品种。","type":"0","source_link":null,"edited_at":1358130983000,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200896,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/22815913","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":540,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-01-14 10:35","expend":false,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"<a href=\"http://xueqiu.com/S/SH600535\"   target=\"_blank\">$天士力(SH600535)$</a> 恭喜天士力再创新高，国家战略奠定天士力两千亿市值基石，两市最佳中线投资品种。","source":"雪球"},{"id":22815029,"user_id":6785033954,"title":"本周股评家最看好的个股名单","created_at":1358123846000,"retweet_count":0,"reply_count":0,"fav_count":0,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"8人次推荐：(1个) 奥维通信(002231) 7人次推荐：(2个) 拓维信息(002261) 中原特钢(002423) 6人次推荐：(4个) 北方国际(000065) 北纬通信(002148) 杰瑞股份(002353) 二 六 三(002467) 5人次推荐：(6个) 北方导航(600435) 华锐风电(601558) 华映科技(000536) 西南合成(000788) 中航精机(002013) 宇顺...","type":"3","source_link":null,"edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200896,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/22815029","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":781,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-01-14 08:37","expend":true,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"8人次推荐：(1个)<br>　　奥维通信(002231)<br>　　7人次推荐：(2个)<br>　　拓维信息(002261)<br>　　中原特钢(002423)<br>　　6人次推荐：(4个)<br>　　北方国际(000065)<br>　　北纬通信(002148)<br>　　杰瑞股份(002353)<br>　　二 六 三(002467)<br>　　5人次推荐：(6个)<br>　　北方导航(600435)<br>　　华锐风电(601558)<br>　　华映科技(000536)<br>　　西南合成(000788)<br>　　中航精机(002013)<br>　　宇顺电子(002289)<br>　　4人次推荐：(8个)<br>　　中国卫星(600118)<br>　　青海华鼎(600243)<br>　　*ST 天成(600392)<br>　　航天通信(600677)<br>　　隆基股份(601012)<br>　　ST 传 媒(000504)<br>　　利达光电(002189)<br>　　海南瑞泽(002596)<br>　　3人次推荐：(23个)<br>　　华润双鹤(600062)<br>　　中国船舶(600150)<br>　　香江股份(600162)<br>　　创新资源(600193)<br>　　红星发展(600367)<br>　　三元股份(600429)<br>　　华丽家族(600503)<br>　　天 士 力(600535)<br>　　益佰制药(600594)<br>　　东阳光铝(600673)<br>　　西藏旅游(600749)<br>　　中国太保(601601)<br>　　中航飞机(000768)<br>　　大族激光(002008)<br>　　四维图新(002405)<br>　　欧 菲 光(002456)<br>　　红日药业(300026)<br>　　华谊兄弟(300027)<br>　　华平股份(300074)<br>　　劲胜股份(300083)<br>　　龙源技术(300105)<br>　　富瑞特装(300228)<br>　　南达光电(300346)","source":"雪球"},{"id":22813793,"user_id":6785033954,"title":"","created_at":1358083613000,"retweet_count":1,"reply_count":0,"fav_count":10,"truncated":false,"commentId":0,"retweet_status_id":22767815,"symbol_id":null,"description":"转发//","type":null,"source_link":null,"edited_at":null,"pic":null,"user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200896,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":{"id":22767815,"user_id":6629424952,"title":"怎样开始投资美股——美股开户和汇款经验分享","created_at":1357538864000,"retweet_count":275,"reply_count":384,"fav_count":827,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"2012 年我最重要的经历之一是开设了 A 股和美股账户，在股票投资上我是绝对的新手，没什么好分享的，不过倒是可以分享一下我美股开户和汇款经验给比我更新的新手。 A 股就不说了，如果有疑问券商会帮你搞定，我是选了对我来说最方便的招商证券，因为工资卡是招商银行的。疑问比较多的可能是美股。[...","type":"3","source_link":null,"edited_at":1385812799000,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6629424952,"type":"1","url":null,"description":"雪球网站/app义务测试员","domain":"undozen","stats":null,"blocking":false,"screen_name":"undoZen","verified":false,"verified_type":0,"st_color":"0","allow_all_stock":false,"following":false,"donate_count":0,"verified_description":null,"profile":"/undozen","status_count":695,"last_status_id":39332621,"follow_me":false,"friends_count":205,"city":"海淀区","gender":"m","followers_count":1927,"province":"北京","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/20138/1379258867393-1379258896414.png,community/20138/1379258867393-1379258896414.png!180x180.png,community/20138/1379258867393-1379258896414.png!50x50.png,community/20138/1379258867393-1379258896414.png!30x30.png"},"retweeted_status":null,"target":"/6629424952/22767815","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":1,"donate_snowcoin":1,"view_count":0,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-01-07 14:07","expend":true,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"2012 年我最重要的经历之一是开设了 A 股和美股账户，在股票投资上我是绝对的新手，没什么好分享的，不过倒是可以分享一下我美股开户和汇款经验给比我更新的新手。<br><br>A 股就不说了，如果有疑问券商会帮你搞定，我是选了对我来说最方便的招商证券，因为工资卡是招商银行的。疑问比较多的可能是美股。[雪球网](<a href=\"http://xueqiu.com/\" title=\"http://xueqiu.com/\"  target=\"_blank\">http://xueqiu.com/</a>)开放注册大概三个月左右了，最近也多了很多到里面询问如何开户和汇款的。<br><br>首先要选择券商，结合自己的经历推荐三个：IB（盈透 InteractiveBrokers）、Scottrade 和 Firstrade。选择券商最重要的是考虑交易手续费和支持服务。<br><br>我一开始用的是 Scottrade，中文支持很好，有繁体中文界面，有一些中文讲解视频（如[解說訂單類型](<a href=\"http://www.youtube.com/watch?v=UVEs0_szd50\" title=\"http://www.youtube.com/watch?v=UVEs0_szd50\"  target=\"_blank\">http://www.youtube.com/watch?v=UVEs0_szd50</a>)），有中文的免费电话（回拨，网页上提交后马上有电话打过来）有问题都能及时咨询。交易手续费用不管多少一律是 7 美元。<br><br>IB 是为专业投资者服务的券商，手续费很便宜，不过有初始注资一万美元以上的要求，还有每月最低消费 10 美元的要求。有一天大家在工作群里讨论券商，我去 IB 的网页上看了看，发现对年轻投资者有优惠。未满 27 岁资金只要求 3000 美元，未满 26 岁月最低消费只要 3 美元。我这个月满 24 岁，对三年内账户资金达到一万美元还是比较有信心的（大不了之后再注资），手续费最低消费优惠还能享受两年，算一下如果我的交易频度大于两个月一次，转过去就是划算的。<br><br>IB 的账户申请很方便，不会像 Scottrade 或 Firstrade 需要寄送纸质资料——如果不急，可以寄平信，如果你要寄 EMS，需要两三百人民币和最快一周左右时间。IB 完全是在线填表，然后上传身份证明和地址证明扫描图片就可以了，白天填完表上传完证明文件，第二天经过美国一个工作日后就发现账户已经开通了，非常便捷。<br><br>IB 有中文简体繁体界面，不过大家都说 IB 的操作界面比较烂。这个得以后我开始在 IB 交易了才知道。<br><br>美股是允许一个人在多个券商开多个账户的（同一券商也可开不同账户），券商之间也方便相互转帐户里面的股票和资金。之前选择 Scottrade 的另一个好处是，根据[这个网页](<a href=\"http://www.bargaineering.com/articles/beware-broker-transfer-out-fees.html\" title=\"http://www.bargaineering.com/articles/beware-broker-transfer-out-fees.html\"  target=\"_blank\">http://www.bargaineering.com/articles/beware-broker-transfer-out-fees.html</a>)，Scottrade 转出股票和资金不收费，而在此列出的其他券商都需要收费（Firstrade 是 50 美元）。不过我已经申请了资产转移，还没到 IB 帐上，要到时候才能真正知道是否收取了费用。<br><br>2013-01-09 更新：前天有网友提[现在 Scottrade 转出要收费了，75 刀](<a href=\"http://www.scottrade.com/online-brokerage/trading-fees-commissions.html#tab7\" title=\"http://www.scottrade.com/online-brokerage/trading-fees-commissions.html#tab7\"  target=\"_blank\">http://www.scottrade.com/online-brokerage/trading-fees-commissions.html#tab7</a>)。今天查 IB 账户已经到账了，果然是扣了 75 刀。如此看来对资金量小的新手来说，更推荐 Firstrade。<br><br>我被同事告知，IB 的一个“坏处”是交易费用太便宜了，让你忍不住多交易；而通常的经验是，交易越多，损失就会越多（不止是手续费，还包括损失掉的赚钱机会）。不过以我自己的亲身体验，觉得新手开户后手痒忍不住多交易是很正常的。<br><br>Firstrade 在这一点就为新手考虑到了。Firstrade 开户后首次注资超过 2000 即可享受 90 天内 250 次免费交易——平均一天好几次，这个频度绝对够用的。条件是这 2000 美元要在 Firstrade 账户内保留一年，如果一年内你有取款操作，这些交易手续费还是会追加扣除的。<br><br>Firstrade 和 Scottrade 差不多，不过比 Scottrade 规模要小。每次交易手续费是 $6.95，因为老板是华人，中文支持做得还不错，在雪球有常驻账号 <a href=\"http://xueqiu.com/n/Firstrade第一理财\"  target=\"_blank\">@Firstrade第一理财</a> ，有问题在雪球 @ 他就可以。和 Scottrade 一样也有免费电话回拨。这家券商周围的人用得比较多，也是雪球里活跃的投资者<a href=\"http://xueqiu.com/n/许志宏\"  target=\"_blank\">@许志宏</a> 力荐的券商。<br><br>貌似在 Firstrade 的期权交易权限比较容易开启，相比 Scottrade 更容易。我现在还不玩这些衍生品，未深入了解。从注册开户经历来看，我估计 IB 也会很容易。<br><br>总的来说有钱人、年轻人，可以考虑选择 IB，新手可以考虑 Firstrade（90天内 250 次免费交易）和 Scottrade（两家都中文服务优秀，手续费差别不大，Scottrade 规模大些）。<br><br>关于汇款，我用过建行和华夏银行的。建行有汇款模版，照着填下来即可。建行比较快，汇过两次都是上午汇出，晚上大概过了 12 个小时查 Scottrade 就已经到账了。我原本选择建行是因为建行对美国银行汇款免手续费。但是实际去汇了才发现，建行是对 Bank of American 免费，而 Scottrade 的收款账号是 U.S. Bank 的，一个美利坚银行，一个合众国银行，完全不一样。<br><br>收费是千分之一加 80 元电报费，千分之一最低按 20 收取，就是最低收费 100 元。华夏银行也是千分之一最低二十，不过免了 80 元的电报费，所以能省不少钱，只是到账时间会多一两天，不急的话推荐选华夏银行。<br><br>有两点注意事项所有银行都一样：<br><br>第一是汇款用途，国内不允许个人向境外投资账户直接汇款注资，不过只要写成培训费就可以了。据说招行很难汇出，不过在招行可以考虑办内地香港两地一卡通账户，工行也有类似服务，我都没办过，具体不太了解，可能以后办了再写写。<br><br>另外一点是境外的汇款结算手续费，选择己方支付的话你可能还得跑银行补缴手续费，选择共同承担即可，这样到账时你会发现少了一点，我用建行两次汇款一千和两千美元，都是被扣 10 美元，用华夏银行汇款一千美元，被扣 15 美元。不过算下来还是华夏银行最划算。如果不着急，用华夏银行一次汇款 3000 美元以上是最划算的。<br><br>要注意 Firstrade 首次注资 2000 美元的要求，你就不能汇款 2000 美元整并选择共同承担汇款费用，要不然到时 Firstrade 里的资金会少于 2000 美元而享受不到那个优惠，我有一个同事就是这样子悲剧了。<br><br>目前暂时就只能分享这些，希望过两年能分享我的美股赚钱经验哈。有什么问题的话可以到雪球网 <a href=\"http://xueqiu.com/n/美股学堂\"  target=\"_blank\">@美股学堂</a> 。雪球<a href=\"http://xueqiu.com/n/小秘书\"  target=\"_blank\">@小秘书</a> 曾经发过一个[美股扫盲一贴通](<a href=\"http://xueqiu.com/4226803442/21990358\" title=\"http://xueqiu.com/4226803442/21990358\"  target=\"_blank\">http://xueqiu.com/4226803442/21990358</a>)值得参考。如果还想了解更多关于美股投资的知识，可以来参加 i美股的[《i美股学堂》——美股常识讲座(1月19日北京)](<a href=\"http://news.imeigu.com/a/1356578689174.html\" title=\"http://news.imeigu.com/a/1356578689174.html\"  target=\"_blank\">http://news.imeigu.com/a/1356578689174.html</a>)。<br><br>我很幸运因为加入雪球网，一开始树立的价值投资的理念就是正确的。但总觉得有点小小的遗憾啊。年轻人有时间，输的起（只要不是借钱去输就行），多搞点投机甚至像同事 <a href=\"http://xueqiu.com/n/Ricky\"  target=\"_blank\">@Ricky</a> 那样一入行搞的就是 Day Trade 也未尝不可。年纪轻轻就搞价值投资，有点像是说反正你到老年时候运动可能主要是高尔夫，那不如从年轻开始就只打高尔夫得了。年轻人，觉得多丰富自己的经历才是正经事。而且年轻人的投资收益率最大的其实是[对自己人力资源的投资](<a href=\"http://xueqiu.com/9255413612/22550684\" title=\"http://xueqiu.com/9255413612/22550684\"  target=\"_blank\">http://xueqiu.com/9255413612/22550684</a>)。<br><br>Updated on 2013-09-05<br><br>这个文章写完放在这好几个月都还不断有人在看，我很欣慰。来更新一下。<br><br>现在 Scottrade 开户更方便了，也完全不需要寄送纸质材料，只要传真或者扫描并发送 email 身份证明文件，之后在网站填写电子版 WBEN8 即可。和 IB 一样方便了。<br><br>如果想注册 IB，不嫌麻烦的话，可以先告诉我你的姓名和 email 地址，然后我发送邀请链接给你。不行就算了，因为 IB 达成推荐奖励的条件非常苛刻，我几乎不指望。<br><br>Updated on 2013-11-30<br><br>就不帮大家推荐 IB 注册了，因为达成推荐奖励的条件非常苛刻，有兴趣的可以自己直接进入 IB 主页注册，有任何问题请 <a href=\"http://xueqiu.com/n/IB盈透证券\"  target=\"_blank\">@IB盈透证券</a>","source":"雪球"},"target":"/6785033954/22813793","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":467,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-01-13 21:26","expend":false,"canEdit":false,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"转发//","source":"雪球"},{"id":22812376,"user_id":6785033954,"title":"北京城区多处PM2.5指数突破900,最高接近1000濒临&#34;爆表&#34;(受益股)","created_at":1358065337000,"retweet_count":11,"reply_count":5,"fav_count":20,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":" 空气治理概念股一览： PM2.5检测：天瑞仪器、华测检测、创元科技； 空气检测：先河环保、聚光科技、雪迪龙； SO2、NOX处理工程：龙净环保、国电清新、九龙电力、永清环保、龙源技术、盛运股份、燃控科技； 其他废气处理工程：三维丝、科林环保、天立环保、菲达环保； 空气净化器：创元科技、横店...","type":"3","source_link":null,"edited_at":null,"pic":"http://xqimg.imedao.com/13c32fcd2ae3a3fd055e07e6.jpg!thumb.jpg,http://xqimg.imedao.com/13c32fd10803c3fef200e08e.jpg!thumb.jpg,http://xqimg.imedao.com/13c32fd2a84463fe5fb91036.jpg!thumb.jpg","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200896,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/22812376","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":707,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-01-13 16:22","expend":true,"canEdit":true,"firstImg":"http://xqimg.imedao.com/13c32fcd2ae3a3fd055e07e6.jpg!thumb.jpg","topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"<img class=\"ke_img\" src=\"http://xqimg.imedao.com/13c32fcd2ae3a3fd055e07e6.jpg!custom.jpg\" /><br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13c32fd10803c3fef200e08e.jpg!custom.jpg\" /><br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13c32fd2a84463fe5fb91036.jpg!custom.jpg\" /><br><br><br><br>空气治理概念股一览：<br>　　PM2.5检测：天瑞仪器、华测检测、创元科技；<br>　　空气检测：先河环保、聚光科技、雪迪龙；<br>　　SO2、NOX处理工程：龙净环保、国电清新、九龙电力、永清环保、龙源技术、盛运股份、燃控科技；<br>　　其他废气处理工程：三维丝、科林环保、天立环保、菲达环保；<br>　　空气净化器：创元科技、横店东磁、雪莱特；<br>　　抗菌口罩：天津泰达和龙头股份。<br><br>相关概念股包括：<br>　　污水处理：兴源过滤、碧水源、津膜科技、万邦达<br>　　环境监测：创元科技、聚光科技、先河环保<br>　　脱硫脱硝：国电清新、燃控科技、龙源技术、九龙电力、三维丝、菲达环保<br>　　固废处理：东江环保、桑德环境、维尔利<br>　　土壤修复：永清环保、铁汉生态","source":"雪球"},{"id":22809975,"user_id":6785033954,"title":"2012年度中国最具竞争力医药上市公司20强企业排名","created_at":1357999327000,"retweet_count":9,"reply_count":9,"fav_count":17,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"2012年度中国最具竞争力医药上市公司20强企业排名 排名公司名称股票代码上市地点产业得分管理得分资本得分管理者得分资源得分总分 1天士力600535上海9.410.5611.47.137.0545.54 2康美药业600518上海1011.410.26.186.1143.89 3恒瑞医药600276上海7.810.5610.87.356.8443.34 4云南白药000538深圳6.41...","type":"3","source_link":null,"edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200896,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/22809975","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":723,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-01-12 22:02","expend":true,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"2012年度中国最具竞争力医药上市公司20强企业排名<br><br>排名公司名称股票代码上市地点产业得分管理得分资本得分管理者得分资源得分总分<br>1天士力600535上海9.410.5611.47.137.0545.54<br>2康美药业600518上海1011.410.26.186.1143.89<br>3恒瑞医药600276上海7.810.5610.87.356.8443.34<br>4云南白药000538深圳6.410.9211.76.767.3543.13<br>5复星医药600196上海9.410.089.67.136.2542.46<br>6国药控股1099香港109.69.36.477.0542.43<br>7东阿阿胶000423深圳611.5211.76.186.9142.31<br>8迈瑞医疗MR纽约8.29.610.86.806.3141.71<br>9爱尔眼科300015创业板9.69.69.66.406.0941.29<br>10威高股份1066香港7.810.3210.56.505.9241.04<br>10中国生物制药1177香港8.68.6410.26.766.8441.04<br>12益佰制药600594上海89.7211.16.185.8240.82<br>13上海医药601607上海9.610.88.75.456.2540.81<br>14华海药业600521上海9.210.089.36.245.7640.58<br>15同仁堂600085上海8.29.969.65.557.1940.50<br>16人福医药600079上海9.610.088.76.085.8440.30<br>17双鹭药业002038中小板710.0811.16.165.7240.06<br>18科伦药业002422中小板8.211.527.56.625.6739.51<br>19仁和药业000650深圳8.69.1210.55.445.6839.34<br>20新华医疗600587上海9.2995.876.0439.11<br><br>　　2012年度最具投资价值医药上市公司10强名单<br>　　<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;天士力　　　&nbsp; &nbsp;　恒瑞医药<br>　　云南白药　　&nbsp; &nbsp;　康美药业<br>　　片仔癀　　　　　国药控股<br>　　东阿阿胶　　　　华润三九<br>　　迈瑞医疗　　　　恩华药业","source":"雪球"},{"id":22809475,"user_id":6785033954,"title":"","created_at":1357991672000,"retweet_count":0,"reply_count":0,"fav_count":0,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"关注股票<a href=\"http://xueqiu.com/S/PRE317\"   target=\"_blank\">$中信国健(PRE317)$</a>。","type":"0","source_link":"http://xueqiu.com/portfolios","edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200896,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/22809475","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":585,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-01-12 19:54","expend":false,"canEdit":false,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"关注股票<a href=\"http://xueqiu.com/S/PRE317\"   target=\"_blank\">$中信国健(PRE317)$</a>。","source":"自选股"},{"id":22809227,"user_id":6785033954,"title":"","created_at":1357986860000,"retweet_count":0,"reply_count":0,"fav_count":1,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"在￥66.80时关注股票<a href=\"http://xueqiu.com/S/SZ000538\"   target=\"_blank\">$云南白药(SZ000538)$</a>。","type":"0","source_link":"http://xueqiu.com/portfolios","edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200896,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/22809227","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":683,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-01-12 18:34","expend":false,"canEdit":false,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"在￥66.80时关注股票<a href=\"http://xueqiu.com/S/SZ000538\"   target=\"_blank\">$云南白药(SZ000538)$</a>。","source":"自选股"},{"id":22809226,"user_id":6785033954,"title":"","created_at":1357986833000,"retweet_count":0,"reply_count":0,"fav_count":0,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"在￥15.76时关注股票<a href=\"http://xueqiu.com/S/SH600197\"   target=\"_blank\">$伊力特(SH600197)$</a>。","type":"0","source_link":"http://xueqiu.com/portfolios","edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200896,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/22809226","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":675,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-01-12 18:33","expend":false,"canEdit":false,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"在￥15.76时关注股票<a href=\"http://xueqiu.com/S/SH600197\"   target=\"_blank\">$伊力特(SH600197)$</a>。","source":"自选股"},{"id":22809223,"user_id":6785033954,"title":"","created_at":1357986776000,"retweet_count":0,"reply_count":0,"fav_count":0,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"在￥24.11时关注股票<a href=\"http://xueqiu.com/S/SH601633\"   target=\"_blank\">$长城汽车(SH601633)$</a>。","type":"0","source_link":"http://xueqiu.com/portfolios","edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200896,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/22809223","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":666,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-01-12 18:32","expend":false,"canEdit":false,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"在￥24.11时关注股票<a href=\"http://xueqiu.com/S/SH601633\"   target=\"_blank\">$长城汽车(SH601633)$</a>。","source":"自选股"},{"id":22809221,"user_id":6785033954,"title":"","created_at":1357986739000,"retweet_count":0,"reply_count":0,"fav_count":0,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"在￥26.00时关注股票<a href=\"http://xueqiu.com/S/SZ000651\"   target=\"_blank\">$格力电器(SZ000651)$</a>。","type":"0","source_link":"http://xueqiu.com/portfolios","edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200896,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/22809221","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":670,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-01-12 18:32","expend":false,"canEdit":false,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"在￥26.00时关注股票<a href=\"http://xueqiu.com/S/SZ000651\"   target=\"_blank\">$格力电器(SZ000651)$</a>。","source":"自选股"},{"id":22809214,"user_id":6785033954,"title":"","created_at":1357986575000,"retweet_count":0,"reply_count":0,"fav_count":0,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"在￥102.67时关注股票<a href=\"http://xueqiu.com/S/SH600436\"   target=\"_blank\">$片仔癀(SH600436)$</a>。","type":"0","source_link":"http://xueqiu.com/portfolios","edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200896,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/22809214","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":647,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-01-12 18:29","expend":false,"canEdit":false,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"在￥102.67时关注股票<a href=\"http://xueqiu.com/S/SH600436\"   target=\"_blank\">$片仔癀(SH600436)$</a>。","source":"自选股"}],"page":368};
  SNB.data.statusType = "";
  SNB.data.isSelf = false;
  SNB.data.who = '他';
  SNB.data.route = '';
  seajs.use(['SNB.status.js', 'SNB.newProfile.js']);
})($);</script></div><script>seajs.use(['widget/donate_tooltip'], function () {
  $('body')
    .on('click', function (e) {
      var $this =  $(e.target);
      
      if (!$this.parents('.set-sub-menu').length) {
        $('.set-sub-menu').hide();
      }
    })
    .on('mouseenter', '.status-list li', function () {
      var $this = $(this);
      
      if ($this.find('.btn-sub-menu').length) {
        $this.find('.btn-sub-menu').addClass('hover');
      }
    })
    .on('mouseleave', '.status-list li', function () {
      var $this = $(this);
      
      if ($this.find('.btn-sub-menu').length) {
        $this.find('.btn-sub-menu').removeClass('hover');
      }
    });
});

</script></div></div></div><div id="footer"><div class="risk">提示：雪球里任何用户或者嘉宾的发言，都有其特定立场，投资决策需要建立在独立思考之上。</div><div class="copyright"><a href="/about/faq" target="_blank">常见问题</a><a href="/about/contact-us" target="_blank">联系方式</a><a href="/about/jobs" target="_blank">加入我们</a><a href="/about/company" target="_blank">关于雪球</a><a>© 2015 XUEQIU.COM</a><a href="http://www.miibeian.gov.cn/" target="_blank">京ICP证100666号</a><span>京公网安备 11010502026957</span></div></div><script>var _hmt = _hmt || [];
(function () {
  var hm = document.createElement("script");
  hm.src = "https://hm.baidu.com/hm.js?1db88642e346389874251b5a1eded6e3";
  var s = document.getElementsByTagName("script")[0];
  s.parentNode.insertBefore(hm, s);
})();</script><script>var _gaq = _gaq || [];
_gaq.push(['_setAccount', 'UA-16079156-4']);
_gaq.push(['_setDomainName', 'none']);
_gaq.push(['_trackPageview']);

(function () {
  var ga = document.createElement('script');
  ga.type = 'text/javascript';
  ga.async = true;
  ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
  var s = document.getElementsByTagName('script')[0];
  s.parentNode.insertBefore(ga, s);
})();

window.onerror = function (message, file, line) {
  var sFormattedMessage = '[' + file + ' (' + line + ')]' + message;
  _gaq.push(['_trackEvent', 'Exceptions', 'Application', sFormattedMessage, null, true]);
}</script><script>jQuery(function ($) {
  $('.cube-invite').on('click', function () {
    var href = $.trim($(this).attr('href'));
    if (window._hmt) {
      _hmt.push(['_trackEvent', 'cube-invite', 'click', href]);
    }
  });
});</script></body></html>